{"study_id": 105343, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the hepatotoxic potential of ramipril, an ACE inhibitor, and its association with elevated alanine aminotransferase (ALT) levels.", "results_summary": "The study found that ramipril was associated with significant liver injury, evidenced by a >35-fold increase in ALT upon rechallenge, and identified 65 cases of ramipril-associated hepatotoxicity in the FAERS database.", "population_specificity": "A 40-year-old male patient and additional cases from the FAERS database (2009-2011).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:35.791306+00:00"}
{"study_id": 105341, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy and safety of combined prednisolone and lamivudine therapy versus prednisolone monotherapy in inactive HBV carriers with IgA nephropathy, focusing on proteinuria remission and HBV reactivation.", "results_summary": "Combined therapy showed higher rates of complete proteinuria remission (65.52% vs. 52.94%) and prevented HBV reactivation and significant ALT elevation (0% vs. 17.65%) compared to monotherapy. Monotherapy was associated with HBV reactivation and liver impairment in some patients.", "population_specificity": "Chinese adults who were inactive HBV carriers with concurrent IgA nephropathy (proteinuria \u2265 3.5 g/day).", "effective_dosage": "Prednisolone 1 mg/kg/day for 2 months (tapered gradually, total duration 12 months); lamivudine 100 mg/day (started 2 weeks before prednisolone and continued for 6 months after withdrawal).", "study_duration": "18 months (12 months of prednisolone treatment, 6 months post-withdrawal lamivudine).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:37.006222+00:00"}
{"study_id": 105344, "supplement_id": 863, "safety_score": "90", "efficacy_score": 20, "quality_score": 70, "study_goal": "The researchers aimed to investigate the effects of dried purple carrot (containing anthocyanins and phenolic acids) on metabolic and inflammatory markers, including alanine amino transferase, in obese males.", "results_summary": "The study found no significant changes in alanine amino transferase levels, indicating the intervention was safe, but it did not demonstrate efficacy in improving metabolic or inflammatory markers. High density lipoprotein cholesterol was lower in the intervention group.", "population_specificity": "16 obese males (aged 53.1 \u00b1 7.6 years, mean BMI 32.8 \u00b1 4.6 kg/m\u00b2) with normal lipid and inflammatory markers.", "effective_dosage": "118.5 mg/day of anthocyanins and 259.2 mg/day of phenolic acids.", "study_duration": "4 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:38.987532+00:00"}
{"study_id": 105347, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to outline current practices and emerging concepts in safety pharmacology studies, including methodologies for evaluating potential adverse effects of new chemical entities.", "results_summary": "The abstract discusses general approaches in safety pharmacology but does not provide specific findings related to Alanine's effects. It highlights emerging concepts like frontloading, parallel assessment, and biomarker use to enhance safety evaluations.", "population_specificity": "Not specified (focus is on general safety pharmacology practices).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:42.240299+00:00"}
{"study_id": 105346, "supplement_id": 863, "safety_score": "95", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the dietary safety of Whole Algalin Protein (WAP) from Chlorella protothecoides, including genotoxic potential and food allergy likelihood.", "results_summary": "The study found no treatment-related adverse effects in rodents at any dosage, with no mutagenicity, clastogenicity, or skin sensitization observed. The NOAEL was established at high WAP concentrations (4805 mg/kg/day in males, 5518 mg/kg/day in females).", "population_specificity": "Rodents (rats and mice)", "effective_dosage": "0, 25,000, 50,000, or 100,000 ppm WAP in feed", "study_duration": "92-93 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:42.490948+00:00"}
{"study_id": 105345, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to estimate the effect of obstructive sleep apnea (OSA) on serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels and investigate its influence on the histological severity of nonalcoholic fatty liver disease (NAFLD).", "results_summary": "The study found that OSA patients had significantly higher ALT (13.3%) and AST (4.4%) levels compared to controls, as well as a 2.6-fold higher risk of liver fibrosis when NAFLD was present. OSA was also associated with liver fibrosis but not lobular inflammation.", "population_specificity": "Patients with obstructive sleep apnea (OSA) and controls, totaling 668 OSA patients and 404 controls.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:42.512205+00:00"}
{"study_id": 105349, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effects of obeticholic acid (OCA) on insulin sensitivity and liver markers in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus.", "results_summary": "OCA administration (25 mg and 50 mg) for 6 weeks increased insulin sensitivity, reduced liver enzymes (alanine aminotransferase and \u03b3-glutamyltransferase), and decreased markers of liver fibrosis, with no significant difference in adverse events compared to placebo.", "population_specificity": "Patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus.", "effective_dosage": "25 mg or 50 mg once daily.", "study_duration": "6 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:44.874792+00:00"}
{"study_id": 105348, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 35, "study_goal": "The researchers aimed to investigate the clinical presentation and diagnostic process of hepatic myelopathy in two patients with spastic paraparesis, noting normal alanine aminotransferase levels among other findings.", "results_summary": "The study found normal alanine aminotransferase levels in both patients, suggesting no liver enzyme elevation related to alanine metabolism. Other findings included pancytopenia, elevated plasma ammonia, and esophageal varices, but no direct effects of alanine were discussed.", "population_specificity": "Two men aged 59 and 43 years with slowly progressive spastic paraparesis and liver-related abnormalities.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:45.059164+00:00"}
{"study_id": 105351, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were examining the role of alanine aminotransferase (ALT) as a biomarker for alcohol abuse and related organ damage.", "results_summary": "The abstract mentions ALT as a well-validated biomarker for screening and monitoring excessive alcohol intake and related disorders, but does not provide specific results regarding its efficacy or safety.", "population_specificity": "General population, with potential focus on individuals with alcohol abuse or related conditions.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:45.539167+00:00"}
{"study_id": 105350, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were comparing the effectiveness of different hepatic artery treatments (TACE, TAE, TAI) for hepatocellular carcinoma (HCC), not specifically evaluating alanine.", "results_summary": "The study found that TACE and TAE were more effective in reducing tumor size than TAI, with reversible liver function damage observed in TACE and TAE groups. Alanine aminotransferase (ALT) changes were noted but not the primary focus.", "population_specificity": "418 patients with a first diagnosis of hepatocellular carcinoma (HCC).", "effective_dosage": "Not available", "study_duration": "Data collected preoperatively and one month post-treatment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:45.770820+00:00"}
{"study_id": 105352, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers reviewed the role of alanine expansions in congenital central hypoventilation syndrome (CCHS) and compared it with other genetic disorders affecting respiratory control.", "results_summary": "The study found that CCHS is characterized by alanine expansions in the PHOX2B gene, leading to impaired ventilatory chemosensitivity. It also highlighted the broader genetic and clinical aspects of respiratory control disorders in CCHS, RTT, and PWS.", "population_specificity": "Individuals with rare genetic disorders (CCHS, RTT, PWS) affecting respiratory control.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:47.425720+00:00"}
{"study_id": 105353, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess whether changes in alanine aminotransferase (ALT) levels reflect improvements in liver histology in patients with non-alcoholic steatohepatitis (NASH) treated with vitamin E.", "results_summary": "Vitamin E therapy led to ALT normalization in 48% of patients, associated with improved liver histology (NAS scores), but not fibrosis. Weight loss enhanced these effects, while weight gain worsened outcomes in placebo recipients.", "population_specificity": "Patients with non-alcoholic steatohepatitis (NASH)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:50.360250+00:00"}
{"study_id": 105354, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers investigated the effect of GFT505, a dual PPAR-\u03b1/\u03b4 agonist, on peripheral and hepatic insulin sensitivity, including its impact on alanine aminotransferase levels.", "results_summary": "GFT505 improved peripheral and hepatic insulin sensitivity, reduced fasting plasma triglycerides and LDL cholesterol, and significantly lowered liver enzyme concentrations, including alanine aminotransferase (-20.5%). No safety concerns or PPAR\u03b3 activation were observed.", "population_specificity": "Twenty-two abdominally obese insulin-resistant males.", "effective_dosage": "80 mg/day", "study_duration": "8-week treatment periods", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:50.630360+00:00"}
{"study_id": 105355, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers aimed to compare the severity and persistence of parenteral nutrition-associated cholestasis (PNAC) between small for gestational age (SGA) and appropriate for gestational age (AGA) very low birth weight (VLBW) infants, with a focus on alanine aminotransferase levels.", "results_summary": "SGA infants exhibited earlier onset, longer persistence, and more severe PNAC compared to AGA infants, including higher and more persistent elevation of alanine aminotransferase. Severe PNAC was significantly more frequent in SGA infants.", "population_specificity": "Very low birth weight (VLBW) infants, divided into small for gestational age (SGA) and appropriate for gestational age (AGA) groups.", "effective_dosage": "Not specified", "study_duration": "Monitoring occurred over 13 weeks of life.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:51.610369+00:00"}
{"study_id": 105356, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to compare computerized techniques, pathologist visual scoring, and clinical parameters for quantifying hepatic steatosis, including assessing correlations with alanine aminotransferase.", "results_summary": "The study found no statistically significant relationships between alanine aminotransferase and hepatic steatosis quantification methods, though correlations were observed with other clinical parameters like body mass index and albumin.", "population_specificity": "Pediatric and adult liver samples, including frozen section and permanent specimens (n=59).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:53.073396+00:00"}
{"study_id": 105361, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to characterize changes in liver histology over time in HCV-infected children, including the role of serum alanine aminotransferase (ALT) levels.", "results_summary": "The study found that while most children showed minimal histologic progression, 29.5% had increased fibrosis severity over a mean interval of 5.8 years. Serum ALT levels did not change significantly between biopsies.", "population_specificity": "44 untreated HCV-infected children without concurrent liver diseases, aged 8.6 to 14.5 years.", "effective_dosage": "Not specified", "study_duration": "Mean interval between biopsies was 5.8 \u00b1 3.5 years.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:53.967237+00:00"}
{"study_id": 105357, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the outcomes of radioembolization with Yttrium-90 resin microspheres between elderly (\u226570 years) and younger (<70 years) patients with unresectable hepatocellular carcinoma (HCC).", "results_summary": "The study found that radioembolization was equally well-tolerated and effective in both elderly and younger patients, with no significant differences in survival or adverse events between the groups. Adverse events were predominantly mild and short-lived.", "population_specificity": "Patients with unresectable HCC who either progressed after prior treatments or were poor candidates for chemoembolization.", "effective_dosage": "Not mentioned", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:54.012609+00:00"}
{"study_id": 105359, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate biochemical changes, including alanine transaminase levels, in patients with obstructive jaundice before and after percutaneous transhepatic biliary drainage (PTBD) to predict outcomes.", "results_summary": "Alanine transaminase levels were significantly lower on the fifth day after PTBD compared to pre-treatment values, indicating improved liver function. The study did not focus on alanine as a supplement but rather as a biomarker of liver health.", "population_specificity": "47 patients with obstructive jaundice secondary to malignant lesions.", "effective_dosage": "Not applicable (alanine was measured as a biomarker, not administered).", "study_duration": "Measurements were taken before, at the fifth hour after, and on the fifth day after PTBD.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:54.206636+00:00"}
{"study_id": 105362, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether exercise training without dietary restriction could improve liver function and related markers in obese, middle-aged men with abnormal liver function.", "results_summary": "Exercise training, despite modest weight reduction, significantly improved liver function markers (alanine aminotransferase, gamma glutamyl transpeptidase), insulin resistance, and adiponectin levels, while reducing inflammation and oxidative stress markers in subjects with suspicious liver fibrosis.", "population_specificity": "Obese, middle-aged men with abnormal liver function and suspicious liver fibrosis.", "effective_dosage": "Not specified", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:55.667737+00:00"}
{"study_id": 105364, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate whether automation (MODULAR PRE-ANALYTICALS EVO-MPA system) improves data quality in laboratory testing compared to traditional processing methods.", "results_summary": "The study found that the MPA system reduced variability and improved the quality of laboratory test results compared to traditional processing, particularly for alanine aminotransferase (ALT) and other clinical chemistry tests. Significant increases in test values were observed in traditionally processed samples before and after storage, while MPA-processed samples showed fewer changes.", "population_specificity": "100 volunteers (blood donors)", "effective_dosage": "Not applicable", "study_duration": "6 hours (storage duration)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:58.755641+00:00"}
{"study_id": 105363, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare MRI-PDFF and MRS-PDFF with histology-determined steatosis grade to assess changes in liver fat content in NAFLD patients, including monitoring alanine aminotransferase levels.", "results_summary": "MRI-PDFF correlated strongly with MRS-PDFF and was more sensitive than histology in detecting changes in liver fat. Changes in liver fat (measured by MRI-PDFF and MRS-PDFF) paralleled changes in body weight and serum alanine aminotransferase levels.", "population_specificity": "50 patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD), mean age 47.8 \u00b1 11.7 years, mean BMI 30.7 \u00b1 6.5 kg/m\u00b2.", "effective_dosage": "Not specified", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:59.445349+00:00"}
{"study_id": 105365, "supplement_id": 863, "safety_score": "85", "efficacy_score": 20, "quality_score": 90, "study_goal": "The researchers aimed to investigate the safety and efficacy of macitentan, an endothelin receptor antagonist, in treating idiopathic pulmonary fibrosis, with a focus on its impact on forced vital capacity and liver enzyme levels (including alanine aminotransferase).", "results_summary": "The study found no significant difference in forced vital capacity or disease progression between macitentan and placebo. Elevated alanine aminotransferase levels occurred in 3.4% of macitentan-treated subjects, slightly lower than the 5.1% in the placebo group, indicating no major safety concerns.", "population_specificity": "Adults with idiopathic pulmonary fibrosis of <3 years duration and a histological pattern of usual interstitial pneumonia on surgical lung biopsy.", "effective_dosage": "10 mg once daily", "study_duration": "Median exposure was 14.5 months for macitentan and 15.0 months for placebo.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:01.381140+00:00"}
{"study_id": 105370, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were reviewing guidelines and recommendations for the management of chronic hepatitis B, not specifically studying Alanine.", "results_summary": "The abstract does not mention Alanine or its effects, focusing instead on antiviral treatments for hepatitis B.", "population_specificity": "Patients with chronic hepatitis B.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:01.742653+00:00"}
{"study_id": 105368, "supplement_id": 863, "safety_score": "65", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and tolerability of subcutaneous interferon \u03b2-1a, including its effects on alanine aminotransferase levels, in pediatric patients with multiple sclerosis.", "results_summary": "The study found increased alanine aminotransferase levels in 37.9% of patients, indicating a common laboratory abnormality, but overall, the treatment was well tolerated and associated with reduced relapse rates.", "population_specificity": "Pediatric patients (aged younger than 18 years) with multiple sclerosis.", "effective_dosage": "44 \u03bcg and 22 \u03bcg, 3 times weekly.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:01.752220+00:00"}
{"study_id": 105367, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of triple therapy (pegylated interferon/ribavirin with boceprevir or telaprevir) in genotype 1 HCV treatment-experienced cirrhotic patients.", "results_summary": "The study found a high incidence of serious adverse events (40.0%), including death and severe complications (6.4%), but noted a high on-treatment virological response. Independent predictors of adverse outcomes included low platelet count and serum albumin levels.", "population_specificity": "Genotype 1 HCV treatment-experienced patients with compensated cirrhosis.", "effective_dosage": "Not specified for Alanine (study focused on triple therapy).", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:02.134062+00:00"}
{"study_id": 105366, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the safety and efficacy of trans-arterial chemo-embolization (TACE) in very elderly patients with hepatocellular carcinoma (HCC), including changes in liver enzyme measurements such as alanine aminotransferase (ALT).", "results_summary": "The study found that TACE was safe and effective in very elderly patients with HCC, with no significant differences in survival or complication rates compared to younger patients. ALT and AST levels often increased post-TACE, but these changes were not associated with prognosis and occurred similarly across all age groups.", "population_specificity": "Patients with hepatocellular carcinoma (HCC), including those \u2265 75 years old, aged 65-75 years, and younger than 65 years.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:03.037164+00:00"}
{"study_id": 105369, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine whether non-alcoholic fatty liver (NAFL) can progress to steatohepatitis (NASH) with fibrosis and identify risk factors for disease progression.", "results_summary": "The study found that a substantial proportion of NAFL patients progressed to NASH with bridging fibrosis, especially those with metabolic risk factors. Mild inflammation or fibrosis increased progression risk compared to steatosis alone.", "population_specificity": "70 patients with untreated non-alcoholic fatty liver disease (NAFLD) and two biopsies performed more than one year apart.", "effective_dosage": "Not mentioned", "study_duration": "Mean follow-up of 3.7 years (s.d. 2.1)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:03.044331+00:00"}
{"study_id": 105372, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to compare metabolic differences, including alanine levels, in malignant serous effusions from ovarian carcinoma, breast carcinoma, and malignant mesothelioma patients.", "results_summary": "The study found that breast carcinomas and malignant mesotheliomas had higher levels of alanine compared to ovarian carcinomas, suggesting metabolic differences between these cancer types.", "population_specificity": "Patients with malignant serous effusions (95 ovarian carcinomas, 10 breast carcinomas, 10 malignant mesotheliomas).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:07.198417+00:00"}
{"study_id": 105371, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the clinical outcomes of telbivudine and entecavir in chronic hepatitis B patients, focusing on alanine aminotransferase normalization, HBV DNA suppression, viral resistance, and renal function.", "results_summary": "Entecavir showed superior outcomes compared to telbivudine in alanine aminotransferase normalization, undetectable HBV DNA, and lower viral resistance, while both drugs improved renal function, especially in patients with renal insufficiency. The incidence of hepatocellular carcinoma was similar between the two treatments.", "population_specificity": "Chronic hepatitis B patients, matched for age, sex, HBeAg status, and cirrhosis.", "effective_dosage": "Not specified", "study_duration": "At least 2 years or less if resistance developed", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:07.375793+00:00"}
{"study_id": 105375, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to assess the effects of cholesterol-reducing agents (not specifically Alanine) on outcomes in patients with aneurysmal subarachnoid hemorrhage.", "results_summary": "The study found no significant effect of simvastatin on delayed ischemic deficits, with some minor adverse events like elevated liver enzymes (aspartate transaminase or alanine transaminase) in a few patients. No conclusions could be drawn due to insufficient evidence.", "population_specificity": "Patients with aneurysmal subarachnoid hemorrhage.", "effective_dosage": "Not applicable (study focused on simvastatin, not Alanine).", "study_duration": "14 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:10.923243+00:00"}
{"study_id": 105376, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to assess the efficacy of a community-based lifestyle modification program in achieving remission of NAFLD, as measured by intrahepatic triglyceride content.", "results_summary": "The intervention group showed significantly higher remission rates (64%) compared to the control group (20%), with greater reductions in liver fat and body weight. Weight loss of more than 10% was strongly associated with remission, but even modest weight loss (3.0-4.9%) led to remission in 41% of cases.", "population_specificity": "154 adults with NAFLD identified during population screening.", "effective_dosage": "Not specified (lifestyle modification program led by dietitians).", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:11.907362+00:00"}
{"study_id": 105374, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to identify baseline predictors of treatment response, including the role of alanine aminotransferase (ALT) normalization, in chronic hepatitis B patients treated with PEG-IFN and adefovir.", "results_summary": "The study found that combination therapy led to HBsAg loss in 11% of HBeAg-positive and 17% of HBeAg-negative patients. Lower baseline HBsAg levels in HBeAg-negative patients strongly predicted HBsAg loss.", "population_specificity": "Chronic hepatitis B patients (44 HBeAg-positive and 48 HBeAg-negative) with HBV DNA > 100,000 copies/ml.", "effective_dosage": "Not specified for alanine; combination therapy involved PEG-IFN-\u03b12a and adefovir for 48 weeks.", "study_duration": "48 weeks of treatment, followed by 2 years of follow-up.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:12.334457+00:00"}
{"study_id": 105378, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to investigate the role of alanine extensions in protein misfolding diseases, particularly focusing on their biochemical properties and implications in conditions like oculopharyngeal muscular dystrophy (OPMD).", "results_summary": "The study found that alanine extensions in proteins, particularly PABPN1, lead to fibril formation in the N-terminal domain, but this behavior did not extend to the full-length protein. The role of these fibrils in disease pathogenesis remains unclear, though potential therapeutic strategies were identified.", "population_specificity": "Not specified (focus on molecular mechanisms and protein behavior).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:13.877275+00:00"}
{"study_id": 105373, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to compare the efficacy of Peg-IFN\u03b1-2a versus Peg-IFN\u03b1-2b in achieving sustained virological response (SVR) and undetectable HBV-DNA levels in chronic hepatitis B (CHB) patients.", "results_summary": "The study found no significant differences between Peg-IFN\u03b1-2a and Peg-IFN\u03b1-2b in achieving SVR (25% vs. 29.6%) or undetectable HBV-DNA levels (20.8% vs. 22.2%) after 48 weeks of therapy. HBeAg seroconversion occurred only in the Peg-IFN\u03b1-2b group.", "population_specificity": "51 CHB patients (24 Peg-IFN\u03b1-2a, 27 Peg-IFN\u03b1-2b) treated at a liver clinic in Turkey, including HBeAg-positive and negative individuals.", "effective_dosage": "Not specified (48-week therapy with Peg-IFN\u03b1-2a or Peg-IFN\u03b1-2b).", "study_duration": "48 weeks of treatment, with follow-up at 24 weeks post-treatment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:14.390311+00:00"}
{"study_id": 105377, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the relationship between the AST:ALT ratio (which includes alanine aminotransferase, ALT) and anticoagulation control in patients with substance abuse receiving warfarin.", "results_summary": "The study found that an elevated AST:ALT ratio (>2.0) in alcohol abusers correlated with significantly poorer anticoagulation control and a higher risk of major hemorrhage compared to nonusers. A normal AST:ALT ratio (\u22641.5) predicted anticoagulation control and hemorrhage rates similar to nonusers.", "population_specificity": "Veterans receiving warfarin across 100 sites, including those with alcohol abuse, drug abuse, or both.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:14.628061+00:00"}
{"study_id": 105379, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate whether B-cell depletion before enzyme replacement therapy (ERT) initiation could block immune responses against acid alpha-glucosidase (GAA) and improve clinical outcomes in infants with Pompe disease.", "results_summary": "The study found that immunomodulation achieved B-cell depletion without adverse effects, eliminated immune responses against GAA, and allowed accelerated infusion rates, though it did not necessarily prevent the need for invasive ventilation in all subjects.", "population_specificity": "Six infants with Pompe disease, aged 2-8 months (including 4 cross-reacting immunologic material-negative infants).", "effective_dosage": "Not specified for alanine (study focused on rituximab, sirolimus/mycophenolate, and ERT).", "study_duration": "17-36 months of rituximab, sirolimus, and ERT.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:17.994422+00:00"}
{"study_id": 105381, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to determine the risk of liver toxicity associated with pazopanib, an angiogenesis inhibitor, through a systematic review and meta-analysis of clinical trials.", "results_summary": "The study found that pazopanib significantly increased the risk of severe non-fatal hepatotoxicity, including elevated AST, ALT, and bilirubin levels, but did not significantly increase the risk of fatal hepatotoxicity.", "population_specificity": "Cancer patients (advanced renal cell cancer and soft tissue sarcoma)", "effective_dosage": "800 mg daily", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:18.349381+00:00"}
{"study_id": 105380, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and efficacy of lomitapide, an MTP inhibitor, in reducing LDL-C and triglycerides in patients with homozygous familial hypercholesterolemia (hoFH), with a focus on managing adverse effects like elevated alanine aminotransferase levels.", "results_summary": "Lomitapide significantly reduced LDL-C in hoFH patients when combined with other lipid-lowering therapies, with additive effects. Elevated alanine aminotransferase levels (>3x upper limit) were manageable with temporary dose reduction, and liver fat accumulation stabilized over time.", "population_specificity": "Patients with homozygous familial hypercholesterolemia (hoFH).", "effective_dosage": "Not specified (up-titration regimen mentioned).", "study_duration": "Not specified (long-term safety assessment needed).", "interactions": "Concomitant treatment with other lipid-lowering drugs was generally safe.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:18.350648+00:00"}
{"study_id": 105383, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the minimal allopurinol doses necessary to achieve adequate 6-TGN concentrations in combination with low-dose azathioprine in IBD patients with inadequate thiopurine metabolite concentrations.", "results_summary": "Adequate 6-TGN concentrations were achieved with 25-50 mg allopurinol and 50 mg azathioprine in most patients, normalizing MMPN concentrations and liver enzymes. The treatment was well-tolerated, with only one dropout due to nausea.", "population_specificity": "11 azathioprine-pretreated IBD patients with inadequately low 6-TGN concentrations and/or elevated MMPN concentrations and/or elevated liver enzymes.", "effective_dosage": "25-50 mg allopurinol and 50 mg azathioprine daily.", "study_duration": "8 weeks after final dose combination.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:22.031204+00:00"}
{"study_id": 105385, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine whether a composite outcome, including hepatic injury (measured by alanine aminotransferase levels), could serve as an appropriate endpoint for clinical trials in neonatal cardiac surgery.", "results_summary": "The study found that the composite outcome, which included elevated alanine aminotransferase levels as a marker of hepatic injury, was associated with longer hospital stays, increased mechanical ventilation duration, and higher hospital charges in neonates undergoing cardiac surgery. The composite outcome occurred in 39% of patients.", "population_specificity": "Neonates (n=76) undergoing cardiac operations requiring cardiopulmonary bypass.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:22.329302+00:00"}
{"study_id": 105384, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the impact of IL28B SNP rs12979860 and HLA class II alleles on predicting spontaneous viral clearance and individualizing treatment strategies in patients with acute HCV infection.", "results_summary": "Spontaneous viral clearance occurred in 28% of patients, with jaundice and IL28B CC genotype being significant predictors. Treatment timing influenced response rates, particularly in IL28B CT/TT patients, where delayed treatment led to lower efficacy.", "population_specificity": "178 patients with acute HCV infection treated with interferon alone or in combination with ribavirin.", "effective_dosage": "Not specified", "study_duration": "Treatment started within or after 48 weeks from diagnosis.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:22.452800+00:00"}
{"study_id": 105386, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the influence of HCV-RNA levels and genotype on liver-related disease progression in HIV/HCV co-infected individuals.", "results_summary": "HCV seropositive HIV patients had a 9-fold increased risk of liver-related death compared to HCV seronegative patients. HCV-RNA levels and genotype did not influence the risk of death from any cause or liver-related death in viremic patients.", "population_specificity": "HIV/HCV co-infected individuals from the EuroSIDA cohort (13,025 subjects, 4,044 HCVAb+).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:22.518604+00:00"}
{"study_id": 105382, "supplement_id": 863, "safety_score": "60", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetics of oral capecitabine (which includes alanine aminotransferase elevation as a side effect) in children with brainstem or high-grade gliomas.", "results_summary": "The study found that capecitabine with concurrent radiation therapy was generally well tolerated, with dose-limiting toxicities including palmar-plantar erythroderma and elevated alanine aminotransferase. Systemic exposure to capecitabine and metabolites was similar to or slightly lower than predicted based on adult data.", "population_specificity": "Children aged 3-21 years with newly diagnosed intrinsic brainstem or high-grade gliomas.", "effective_dosage": "Starting dose of 500 mg/m\u00b2 twice daily, escalated to 650 mg/m\u00b2 and 850 mg/m\u00b2, followed by 1250 mg/m\u00b2 twice daily for 14 days with a 7-day rest.", "study_duration": "9 weeks of concurrent therapy, followed by a 2-week break and three additional courses.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:23.168325+00:00"}
{"study_id": 105388, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the clinical benefits and safety of everolimus, including its impact on alanine aminotransferase levels, as a treatment for renal cell cancer.", "results_summary": "The study found that everolimus extended progression-free survival in RCC patients but was associated with elevated alanine aminotransferase levels as a grade 3/4 laboratory abnormality.", "population_specificity": "Renal cell cancer (RCC) patients", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:25.499419+00:00"}
{"study_id": 105389, "supplement_id": 863, "safety_score": "70", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to determine the safety, pharmacokinetics, and antitumor activity of IPI-926, a Hedgehog pathway inhibitor, in patients with refractory solid tumors.", "results_summary": "IPI-926 was well tolerated up to 160 mg QD, with reversible adverse effects like elevated liver enzymes and fatigue. Antitumor activity was observed in Hedgehog pathway inhibitor-na\u00efve basal cell carcinoma patients, with nearly a third showing a response at doses \u2265130 mg.", "population_specificity": "Patients with solid tumors refractory to standard therapy (ages 39-87, 32F, 62M).", "effective_dosage": "20 to 210 mg once daily (QD).", "study_duration": "28-day cycles.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:26.811354+00:00"}
{"study_id": 105387, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were investigating the effects of an herbal preparation containing Vernonia cinerea on glycemic control and metabolic parameters in patients with type 2 diabetes, but the study did not specifically focus on Alanine.", "results_summary": "The study found that the herbal preparation significantly reduced glucose, hemoglobin A1c, cholesterol, LDL cholesterol, and triglyceride levels, but no significant changes were observed in alanine aminotransferase levels, indicating no adverse effects on liver function.", "population_specificity": "48 patients with type 2 diabetes mellitus for longer than 6 months.", "effective_dosage": "Not specified for Alanine.", "study_duration": "3 months per treatment phase (6 months total).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:27.164604+00:00"}
{"study_id": 105393, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy of entecavir and telbivudine in treating HBeAg-positive Asian patients with chronic hepatitis B, including their effects on alanine aminotransferase normalization.", "results_summary": "The study found no significant differences in alanine aminotransferase normalization rates between entecavir and telbivudine at 12, 24, and 48 weeks, but telbivudine showed higher HBeAg loss and seroconversion rates.", "population_specificity": "Nucleos(t)ide-naive Asian patients with HBeAg-positive chronic hepatitis B.", "effective_dosage": "Not specified for alanine (study focused on entecavir 0.5 mg/d and telbivudine 600 mg/d).", "study_duration": "Minimum of 12 weeks, with assessments at 12, 24, and 48 weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:32.826180+00:00"}
{"study_id": 105390, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the effects of a 12-week energy-restricted diet on cardiometabolic risk factors in metabolically abnormal obese (MAO) and metabolically healthy but obese (MHO) women, including changes in hepatic enzymes like alanine aminotransferase (ALT).", "results_summary": "The study found that alanine aminotransferase (ALT) levels decreased significantly in both MAO and MHO women after the 12-week intervention (p < 0.001), indicating improved liver function. However, the study did not isolate the effects of alanine itself, as the intervention was a broader dietary change.", "population_specificity": "Nonmorbid obese premenopausal Caucasian women (53 MAO and 25 MHO, aged 19-49, BMI 30-39.9).", "effective_dosage": "Not specified (intervention was an energy-restricted diet, not alanine supplementation).", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:33.151335+00:00"}
{"study_id": 105391, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy of a response-guided combination therapy of peg-IFN \u03b12a and lamivudine in improving HBeAg seroconversion rates in HBeAg-positive chronic hepatitis B patients, with a focus on ALT normalization as a marker of liver health.", "results_summary": "The study found that the combination therapy resulted in 69% ALT normalization at the end of treatment, with sustained effects in early responders. Group A (peg-IFN \u03b12a monotherapy) showed 100% ALT normalization, while Group B (combination therapy) achieved 63% ALT normalization.", "population_specificity": "HBeAg-positive chronic hepatitis B patients", "effective_dosage": "peg-IFN \u03b12a at 135 \u03bcg/week; lamivudine dosage not specified", "study_duration": "52 weeks (with lamivudine added for 12 weeks in some patients)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:33.770347+00:00"}
{"study_id": 105396, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers were investigating the diagnostic and therapeutic response in a case of autoimmune hepatitis (AIH) with markedly enlarged lymph nodes, not specifically studying alanine.", "results_summary": "The study found that corticosteroid therapy effectively reduced liver and lymph node size in a patient with acute AIH, but did not assess alanine's effects.", "population_specificity": "A previously healthy 37-year-old male with autoimmune hepatitis and enlarged lymph nodes.", "effective_dosage": "Not specified (corticosteroid therapy details not provided).", "study_duration": "2 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:34.117985+00:00"}
{"study_id": 105392, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the impact of sociodemographic and clinical factors, including alanine aminotransferase (ALT) levels, on early virological response (EVR) to peginterferon/ribavirin treatment in chronic hepatitis C patients.", "results_summary": "Higher ALT levels were associated with a lower likelihood of achieving EVR. Patients with genotype 1/4, older age, and elevated GGT levels were less likely to achieve EVR, while those with lower ferritin levels and non-1/4 genotypes showed better responses.", "population_specificity": "Chronic hepatitis C patients (n=1014), predominantly male (70%), Caucasian (97%), with mean age 44.3 years.", "effective_dosage": "Peginterferon \u03b1-2a (180 mg) plus ribavirin (800/1000/1200 mg/d).", "study_duration": "12 weeks for EVR assessment, with planned treatment durations of 24 or 48 weeks depending on genotype.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:34.267117+00:00"}
{"study_id": 105395, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to compare the effects of diuretics versus fluid expansion on hemodynamic status and venous congestion in patients with right ventricular infarction and oligoanuria, including changes in alanine aminotransferase levels.", "results_summary": "The study found that diuretics improved blood pressure, heart rate, creatinine levels, and alanine aminotransferase levels compared to fluid expansion, though both treatments similarly triggered diuresis.", "population_specificity": "77 patients with right ventricular extension of inferior or posterior acute myocardial infarction, of which 19 had oligoanuria.", "effective_dosage": "Low dose of furosemide (40 to 80 mg).", "study_duration": "24 hours after treatment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:34.643915+00:00"}
{"study_id": 105397, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the efficacy and safety of a triple therapy (telaprevir, pegylated interferon \u03b12b, and ribavirin) in older Japanese patients with chronic hepatitis C, not specifically studying Alanine.", "results_summary": "The study found no significant difference in sustained virological response (SVR) between older (>60) and younger (\u226460) patients, with SVR rates of 76.6% and 83.9%, respectively. Adverse effects led to treatment discontinuation in 12.5% of patients in each group, with a significant difference in hemoglobin decrease between age groups.", "population_specificity": "Japanese patients with genotype 1b chronic hepatitis C, categorized by age (>60 and \u226460).", "effective_dosage": "Not specified for Alanine.", "study_duration": "12 weeks of triple therapy followed by 12 weeks of dual therapy.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:37.021236+00:00"}
{"study_id": 105394, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to investigate the efficacy of telbivudine in interrupting mother-to-child transmission of HBV and its effects on maternal HBV DNA negative conversion and ALT normalization.", "results_summary": "Telbivudine reduced HBsAg and HBV DNA seroprevalence in newborns and infants, and showed benefits for mothers in HBV DNA negative conversion and ALT normalization, particularly in women with high viral load.", "population_specificity": "Pregnant women with HBV infection.", "effective_dosage": "Not specified", "study_duration": "Late pregnancy (specific duration not mentioned)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:39.537934+00:00"}
{"study_id": 105401, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to examine the associations between liver enzymes (including alanine aminotransferase, ALT) and diabetes risk, and whether these associations varied by race and gender.", "results_summary": "Higher ALT levels were independently associated with increased diabetes risk, with a hazard ratio of 1.68 comparing the highest to lowest quartiles. The associations were similar across races but stronger in black participants.", "population_specificity": "7495 white and 1842 black participants without diabetes from the Atherosclerosis Risk in Communities Study.", "effective_dosage": "Not specified", "study_duration": "Median follow-up of 12 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:42.598400+00:00"}
{"study_id": 105398, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare liver resection and radiofrequency ablation in patients with single hepatocellular carcinoma \u22643 cm and compensated cirrhosis, with a secondary focus on identifying predictors of poor survival and recurrence, including alanine-aminotransferase levels.", "results_summary": "Higher alanine-aminotransferase levels were identified as an independent factor associated with higher recurrence rates in patients with hepatocellular carcinoma. The study did not directly assess alanine's efficacy or safety as a supplement.", "population_specificity": "544 Child-Pugh A cirrhotic patients with single hepatocellular carcinoma \u22643 cm.", "effective_dosage": "Not available", "study_duration": "Not specified for alanine-related outcomes", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:42.712976+00:00"}
{"study_id": 105400, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to compare the efficacy and safety of tocilizumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis, not specifically to evaluate Alanine.", "results_summary": "The study found that tocilizumab monotherapy was superior to adalimumab monotherapy in reducing rheumatoid arthritis symptoms. Adverse events included increased alanine aminotransferase concentrations, but the study did not focus on Alanine's effects.", "population_specificity": "Patients aged 18+ with severe rheumatoid arthritis for 6+ months, intolerant to or inappropriate for methotrexate treatment.", "effective_dosage": "Not applicable (study did not focus on Alanine).", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:43.348955+00:00"}
{"study_id": 105403, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The study aimed to explore the safety and tolerability of eltrombopag in patients with advanced soft tissue sarcoma and thrombocytopenia due to AI chemotherapy, not specifically Alanine.", "results_summary": "The study found that eltrombopag was generally safe with no dose-limiting toxicities, and it increased platelet counts in patients receiving AI chemotherapy. The most common nonhematologic adverse events included increased alanine aminotransferase, but the study did not focus on Alanine's effects.", "population_specificity": "Patients aged 18 or older with histologically confirmed, locally advanced or metastatic soft tissue sarcoma.", "effective_dosage": "75 mg, 100 mg, and 150 mg eltrombopag daily.", "study_duration": "At least 2 chemotherapy cycles.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:44.416711+00:00"}
{"study_id": 105402, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the role of IgG4-associated de novo autoimmune hepatitis (AIH) post-liver transplantation and its response to prednisone and azathioprine therapy, including the normalization of alanine aminotransferase levels.", "results_summary": "The study found that IgG4-associated de novo AIH post-liver transplantation showed severe histological activity but responded well to prednisone and azathioprine therapy, leading to normalized alanine aminotransferase and IgG levels. Early diagnosis and timely management were associated with a good prognosis.", "population_specificity": "A 56-year-old man post-liver transplantation with hepatitis C virus recurrence.", "effective_dosage": "Not specified for alanine (the focus was on prednisone and azathioprine therapy).", "study_duration": "Not specified for alanine (the focus was on post-treatment follow-up).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:44.598311+00:00"}
{"study_id": 105404, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to investigate the hepatoprotective effect of fermented turmeric powder (FTP) on liver function in subjects with elevated alanine transaminase (ALT) levels.", "results_summary": "The FTP group showed a significant reduction in ALT and AST levels compared to the placebo group after 12 weeks, with no severe adverse events reported. GGT levels tended to decrease, while ALP, TB, and lipid levels remained unchanged.", "population_specificity": "Subjects aged 20+ with mild to moderately elevated ALT levels (40-200 IU/L).", "effective_dosage": "3.0 g per day (two capsules three times a day after meals).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:45.562277+00:00"}
{"study_id": 105405, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers investigated whether the presence of autoantibodies (ANA, LKM, SMA, AMA) affects the initiation and efficacy of interferon-based therapy for chronic hepatitis C.", "results_summary": "The study found that autoantibody status did not influence the decision to initiate therapy or the sustained virologic response. Thyroid dysfunction was more frequent in patients with LKM antibodies, but fibrosis stage and alanine transaminase levels were unaffected by antibody status.", "population_specificity": "24,306 patients with chronic hepatitis C, including 8,241 tested for autoantibodies.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:47.156529+00:00"}
{"study_id": 105406, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "To evaluate the efficacy and safety of entecavir (ETV) in patients with advanced schistosomiasis and hepatitis B virus (HBV) co-infection, including its impact on hepatic fibrosis markers and liver function.", "results_summary": "ETV significantly improved hepatic fibrosis markers, reduced Ishak fibrosis scores, increased undetectable HBV DNA levels, and normalized ALT compared to the control group, with no obvious adverse reactions reported.", "population_specificity": "Patients with advanced schistosomiasis and HBV co-infection (n=67).", "effective_dosage": "0.5mg once daily.", "study_duration": "52 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:51.495058+00:00"}
{"study_id": 105407, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy of lactulose (not alanine) in preventing hepatic encephalopathy (HE) in cirrhotic patients with upper gastrointestinal bleeding (UGB).", "results_summary": "Lactulose significantly reduced the incidence of HE (3.2% vs. 16.9%) and improved ammonia levels and cognitive function (NCT scores) compared to the control group. Patients with higher baseline Child-Turcotte-Pugh scores were more likely to develop HE.", "population_specificity": "Cirrhotic patients with upper gastrointestinal bleeding (UGB).", "effective_dosage": "Not specified for alanine (study focused on lactulose).", "study_duration": "6 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:51.913529+00:00"}
{"study_id": 105408, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy and safety of telbivudine versus lamivudine in treating hepatitis B-related cirrhosis, with a focus on serum alanine aminotransferase (ALT) levels and other clinical outcomes.", "results_summary": "Telbivudine and lamivudine showed comparable reductions in ALT levels, with telbivudine demonstrating slightly greater HBeAg loss and seroconversion, though not statistically significant. Both treatments were well tolerated with minor adverse events.", "population_specificity": "165 hepatitis B-related cirrhotic patients (55 compensated, 110 decompensated).", "effective_dosage": "Telbivudine 600 mg/day, lamivudine 100 mg/day.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:52.096217+00:00"}
{"study_id": 105409, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and safety of sequential telbivudine treatment in HBeAg-positive chronic hepatitis B patients with partial responses to pegylated interferon, focusing on outcomes like HBeAg seroconversion, HBV DNA levels, and ALT normalization.", "results_summary": "Sequential telbivudine treatment resulted in higher HBeAg seroconversion (61%) and HBV DNA loss (100%) compared to no sequential treatment, with all patients achieving normal ALT levels and only minor creatine kinase elevation noted.", "population_specificity": "HBeAg-positive chronic hepatitis B patients with partial responses to 48 weeks of pegylated interferon.", "effective_dosage": "600 mg/day of telbivudine.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:53.797483+00:00"}
{"study_id": 105399, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to assess the efficacy and safety of Rehmannia glutinosa acteosides combined with irbesartan for treating primary chronic glomerulonephritis, including monitoring serum alanine aminotransferase levels.", "results_summary": "The combination treatment significantly reduced 24-h proteinuria (36.42%) compared to irbesartan alone (27.97%). Adverse reactions were similarly low in both groups (0.4% vs. 1.2%).", "population_specificity": "479 patients diagnosed with primary chronic glomerulonephritis.", "effective_dosage": "Rehmannia glutinosa acteosides (two 200-mg capsules, bid); irbesartan (one 150-mg tablet, qd).", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:54.160533+00:00"}
{"study_id": 105412, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to compare the efficacy of a new surgical tool (HSVB) with existing methods for controlling bleeding during liver resection, not to evaluate Alanine.", "results_summary": "The study found that HSVB reduced blood loss, operative time, and postoperative hepatic dysfunction compared to other methods, but did not assess Alanine's effects.", "population_specificity": "117 patients undergoing liver resection for cancer.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:54.188306+00:00"}
{"study_id": 105411, "supplement_id": 863, "safety_score": "70", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and efficacy of nab-paclitaxel plus gemcitabine, including the role of alanine aminotransferase as a dose-limiting toxicity, in Chinese patients with advanced pancreatic ductal adenocarcinoma.", "results_summary": "The study found that elevated alanine aminotransferase was a dose-limiting toxicity, but the maximum-tolerated dose was not reached. The combination therapy showed a favorable safety profile and encouraging antitumor effects, with an overall response rate of 41.67% at the highest dose.", "population_specificity": "Chinese patients with previously untreated advanced pancreatic ductal adenocarcinoma.", "effective_dosage": "Nab-paclitaxel at 80 mg/m\u00b2, 100 mg/m\u00b2, and 120 mg/m\u00b2, plus gemcitabine (1,000 mg/m\u00b2) on days 1 and 8 every 21 days.", "study_duration": "Treatment cycles repeated every 21 days (total of 93 cycles administered).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:56.128525+00:00"}
{"study_id": 105410, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effects of telbivudine therapy on HBV DNA suppression, ALT normalization, HBeAg seroconversion, and viral resistance in chronic hepatitis B patients, including predictors of treatment response.", "results_summary": "The study found that telbivudine therapy showed promising results in HBV DNA suppression, ALT normalization, and HBeAg seroconversion over 1-, 2-, and 3-year periods, with predictors like HBV DNA undetectability and ALT levels at 12 and 24 weeks optimizing therapy. The Chinese EFFORT study also demonstrated positive outcomes for virological response at 24 weeks.", "population_specificity": "HBeAg-positive and -negative chronic hepatitis B (CHB) patients, including pregnant women in the second and third trimesters.", "effective_dosage": "Not specified", "study_duration": "Up to 3 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:56.137876+00:00"}
{"study_id": 105413, "supplement_id": 863, "safety_score": "85", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the safety and efficacy of Chlorella supplementation in reducing liver enzyme levels (ALT and AST) and HCV RNA levels in patients with chronic HCV genotype 1 infection.", "results_summary": "Chlorella supplementation was well tolerated and associated with a significant decrease in ALT levels in 84.61% of patients, though changes in AST and HCV RNA levels were not statistically significant. Quality of life improvements were reported, including increased energy levels and better general health perception.", "population_specificity": "18 adults with chronic HCV genotype 1 infection.", "effective_dosage": "Daily oral supplementation (specific dosage not mentioned).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:00.286207+00:00"}
{"study_id": 105415, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to investigate the potential therapeutic effects of D-alanine as an add-on treatment for schizophrenia, focusing on its role in modulating the glutamatergic NMDA receptor.", "results_summary": "The abstract suggests that D-alanine, along with other substances regulating NMDA receptor activation/inhibition, shows promise in addressing negative symptoms, cognition, and mood in schizophrenia, though specific results for D-alanine are not detailed.", "population_specificity": "Patients with schizophrenia.", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:00.406440+00:00"}
{"study_id": 105414, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) for treating unresectable hepatocellular carcinoma (HCC), not specifically Alanine.", "results_summary": "The study found that TACE demonstrated a 75.0% 2-year survival rate, with 73% response rate (42% complete, 31% partial). Grade 3-4 toxicities included increased alanine aminotransferase levels in 36% of patients, but these were generally transient.", "population_specificity": "Patients with unresectable HCC unsuitable for curative treatment or with no prior therapy for HCC.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Repeated TACE on an as-needed basis; median overall survival was 3.1 years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:01.190942+00:00"}
{"study_id": 105416, "supplement_id": 863, "safety_score": "80", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to assess the clinical efficacy and tolerability of cholic acid (CA) therapy in patients with lipodystrophy and hepatic steatosis, including its effects on serum alanine aminotransferase (ALT) levels.", "results_summary": "CA therapy did not reduce hepatic triglyceride content or serum triglyceride levels, nor did it change AST, ALT, or GGT levels. Two patients experienced mild gastrointestinal side effects (diarrhea and excessive flatus), which resolved after dose reduction.", "population_specificity": "Patients with genetic or autoimmune lipodystrophies and elevated hepatic triglyceride content (n=18).", "effective_dosage": "15 mg/kg per day", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:02.753708+00:00"}
{"study_id": 105418, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate predictors of malignancy in ampullary adenomas, including the role of alanine aminotransferase levels as a potential marker.", "results_summary": "Elevated alanine aminotransferase (>40 IU/L) was associated with malignancy in ampullary adenomas in univariate analysis, but it was not an independent predictor in multivariate analysis. The study identified high-grade dysplasia and ductal dilatation as significant predictors of malignancy.", "population_specificity": "Patients diagnosed with ampullary adenoma on endoscopic biopsy who underwent endoscopic or surgical resection (n=91).", "effective_dosage": "Not available", "study_duration": "Not applicable (retrospective study spanning 1995-2011)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:03.678627+00:00"}
{"study_id": 105417, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to assess the effects of extended-release niacin (ERN) combined with laropiprant (LRPT) on cardiovascular outcomes and safety in high-risk vascular patients, not specifically Alanine.", "results_summary": "The study found that ERN/LRPT increased the risk of myopathy and liver enzyme elevations (alanine transaminase >3\u00d7 upper limit of normal) compared to placebo, particularly in Chinese patients. No specific results regarding Alanine's effects were reported.", "population_specificity": "Patients with occlusive arterial disease at high risk of vascular events.", "effective_dosage": "Not applicable (study focused on ER niacin 2 g plus laropiprant 40 mg daily).", "study_duration": "Median follow-up of 3.9 years.", "interactions": "None mentioned (study noted interactions with simvastatin and ezetimibe, but not Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:03.954354+00:00"}
{"study_id": 105420, "supplement_id": 863, "safety_score": "80", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the antiviral activity, safety, and pharmacokinetics of IDX184 (a liver-targeted nucleotide prodrug) in combination with pegylated interferon-\u03b12a and ribavirin (P/R) for treating genotype-1 HCV in treatment-naive patients.", "results_summary": "IDX184 combined with P/R demonstrated greater antiviral activity than P/R alone, with higher proportions of patients achieving undetectable viral loads. The treatment was well tolerated, with most adverse events being mild or moderate, consistent with P/R-associated effects.", "population_specificity": "Treatment-naive patients with genotype-1 HCV, baseline HCV RNA \u22655 log10 IU/ml, alanine aminotransferase \u22643\u00d7 upper limit of normal, and compensated liver disease.", "effective_dosage": "50 mg once daily, 50 mg twice daily, 100 mg once daily, 150 mg once daily, 100 mg twice daily, and 200 mg once daily.", "study_duration": "14 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:06.404937+00:00"}
{"study_id": 105421, "supplement_id": 863, "safety_score": "95", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine the effects of Nigella sativa oil on blood pressure in healthy volunteers, including its impact on alanine transaminase levels.", "results_summary": "The study found that Nigella sativa oil significantly reduced systolic and diastolic blood pressure without adverse effects, while alanine transaminase levels and other parameters remained unchanged.", "population_specificity": "Healthy volunteers aged 34 to 63 years with systolic BP 110-140 mmHg and diastolic BP 60-90 mmHg.", "effective_dosage": "2.5 mL two times a day (total 5 mL daily).", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:08.235921+00:00"}
{"study_id": 105422, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the safety and durability of darunavir/ritonavir (DRV/r)-based treatment in HIV patients, not specifically Alanine.", "results_summary": "The study found that DRV/r was safe and well-tolerated with few discontinuations due to adverse events, but did not specifically address Alanine's effects.", "population_specificity": "HIV patients in clinical practice, including treatment-na\u00efve and treatment-experienced individuals.", "effective_dosage": "Not mentioned for Alanine.", "study_duration": "24 months of follow-up.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:09.077203+00:00"}
{"study_id": 105425, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the proportion and reasons why anti-HCV-positive patients in Greek tertiary liver centers did not receive antiviral therapy, including the role of alanine transaminase levels.", "results_summary": "The study found that normal alanine transaminase levels were an independent predictor of no antiviral treatment initiation (OR: 1.7). Over 40% of anti-HCV-positive patients did not receive therapy, with loss to follow-up and physician decisions being major factors.", "population_specificity": "Anti-HCV-positive patients visiting tertiary liver centers in Greece (2002-2010).", "effective_dosage": "Not available", "study_duration": "Retrospective study spanning 8 years (2002-2010).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:12.656611+00:00"}
{"study_id": 105424, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to test the reliability of the ANI scoring system, which includes alanine aminotransferase, to distinguish alcoholic liver disease (ALD) from nonalcoholic fatty liver disease (NAFLD).", "results_summary": "The study found that ANI, which incorporates alanine aminotransferase, effectively differentiated ALD from NAFLD with high specificity (96.7%) and sensitivity (84.1%). ANI scores greater than -0.66 indicated ALD, while scores below -0.66 suggested NAFLD.", "population_specificity": "135 patients with fatty liver disease, classified into ALD and NAFLD groups based on pathohistological results, in a Serbian population.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:13.069135+00:00"}
{"study_id": 105423, "supplement_id": 863, "safety_score": "80", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy and safety of nevirapine-based antiretroviral therapy (including alanine aminotransferase monitoring) versus efavirenz-based therapy in HIV and tuberculosis co-infected patients.", "results_summary": "The study found that nevirapine was not non-inferior to efavirenz in achieving virological suppression at 48 weeks, but it was generally safe with a similar rate of grade 3-4 alanine aminotransferase increases (7% vs. 6%). Severe rash occurred in 1% of nevirapine recipients.", "population_specificity": "Adults (\u226518 years) with tuberculosis and previously untreated HIV infection (CD4 cell counts <250 cells per \u03bcL) and normal alanine aminotransferase and bilirubin levels.", "effective_dosage": "Not specified for alanine (monitored as a safety marker).", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:13.829522+00:00"}
{"study_id": 105426, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the hepatoprotective and additive efficacy of total glucosides of paeony (TGP) in combination with methotrexate (MTX) and leflunomide (LEF) for treating active rheumatoid arthritis (RA), focusing on alanine aminotransferase (ALT) levels as a marker of liver toxicity.", "results_summary": "The study found that TGP significantly reduced hepatotoxicity (measured by ALT and AST levels) in RA patients receiving MTX and LEF, with fewer instances of elevated liver enzymes compared to the control group. TGP also showed a trend toward improved clinical response, though this was not statistically significant.", "population_specificity": "204 patients with active rheumatoid arthritis (DAS28 > 3.2) recruited from 3 regional referral centers.", "effective_dosage": "Not specified for TGP; MTX (10 mg/week) plus LEF (20 mg/day).", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:14.578282+00:00"}
{"study_id": 105427, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 65, "study_goal": "The researchers were investigating the effects of a novel APOA-I gene mutation involving alanine duplication on HDL metabolism and coronary heart disease.", "results_summary": "The study found that the mutation led to abnormal lipid binding properties in apoA-I, impaired reverse cholesterol transport, and probable enhanced clearance, contributing to premature coronary heart disease. Only very small pre-beta-1 HDL and large alpha-2 HDL were present, indicating dysfunctional HDL metabolism.", "population_specificity": "A 61-year-old white man of European ancestry with significant coronary heart disease and marked HDL deficiency.", "effective_dosage": "Not specified for alanine (study focused on genetic mutation effects).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:14.891745+00:00"}
{"study_id": 105428, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 65, "study_goal": "The researchers aimed to determine whether regular tea/coffee consumption (methylxanthines) affects ALT and AST levels in saliva and serum among oral cancer and precancerous patients with tobacco habits.", "results_summary": "The study found statistically significant increases in ALT and AST levels in both saliva and serum of precancerous and oral cancer patients compared to controls, suggesting impaired salivary gland antioxidant function due to long-term methylxanthine exposure.", "population_specificity": "Males aged 20-45 years from western Maharashtra, India, with smoking/smokeless tobacco habits and regular tea/coffee consumption.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:16.266590+00:00"}
{"study_id": 105429, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were analyzing the outcomes of phase I trials involving targeted agents and locoregional therapies for patients with advanced cholangiocarcinoma and gallbladder carcinoma, with a focus on factors like elevated alanine aminotransferase (ALT) and their association with progression-free survival.", "results_summary": "Elevated ALT (>56IU/L) was associated with shorter progression-free survival in univariate analysis. The study did not specifically evaluate the effects of alanine supplementation or its direct therapeutic role.", "population_specificity": "Patients with advanced cholangiocarcinoma (n=34) and gallbladder carcinoma (n=6), median age 60 years.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:17.428253+00:00"}
{"study_id": 105430, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to review the pharmacological properties of novel oral anticoagulants, including their effects and restrictions in patients with impaired hepatic function, with mentions of alanine aminotransferase levels.", "results_summary": "The study found that apixaban can be used cautiously in patients with mild to moderate hepatic impairment or elevated alanine aminotransferase levels (>2\u00d7 ULN), but is contraindicated in severe hepatic impairment or coagulopathy.", "population_specificity": "Patients with impaired hepatic function, including those with elevated alanine aminotransferase levels.", "effective_dosage": "Not specified for alanine.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:20.470609+00:00"}
{"study_id": 105431, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were reviewing the characteristics and clinical trial data of crizotinib in ALK-positive non-small cell lung cancer (NSCLC), not specifically studying Alanine.", "results_summary": "The abstract does not discuss Alanine's effects; it focuses on crizotinib's efficacy and safety in ALK-positive NSCLC patients.", "population_specificity": "Patients with ALK-positive, advanced non-small cell lung cancer (NSCLC).", "effective_dosage": "Not mentioned (for Alanine).", "study_duration": "Not mentioned (for Alanine).", "interactions": "None mentioned (for Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:21.703080+00:00"}
{"study_id": 105432, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to assess the long-term safety and efficacy of ketoconazole foam, 2%, for seborrheic dermatitis, not Alanine.", "results_summary": "The study found that ketoconazole foam had a favorable long-term safety profile and maintained efficacy in treating seborrheic dermatitis, with minimal treatment-related adverse events. Alanine aminotransferase increase was noted in 1% of subjects.", "population_specificity": "Immunocompetent patients aged \u226512 years with seborrheic dermatitis.", "effective_dosage": "Ketoconazole foam, 2%, applied twice daily as required.", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:22.298314+00:00"}
{"study_id": 105433, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers were comparing the effectiveness and invasiveness of endovascular intervention versus open surgery for treating hepatic artery complications in pediatric liver transplant patients, not specifically evaluating Alanine.", "results_summary": "The study found that endovascular intervention was less invasive and had shorter operation times compared to open surgery, but had a higher recurrence rate of hepatic artery stenosis. Posttreatment AST/ALT levels were lower in the endovascular group.", "population_specificity": "Pediatric patients with hepatic artery complications after living donor liver transplantation.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:23.617701+00:00"}
{"study_id": 105435, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare the efficacy of nucleoside or nucleotide analog monotherapies, including their effects on normalizing alanine aminotransferase levels, in treating chronic hepatitis B.", "results_summary": "Tenofovir was found to be the most effective in normalizing alanine aminotransferase levels, reducing HBV DNA, and inducing HBeAg seroconversion after one year of treatment. The study ranked therapies to guide optimal treatment selection.", "population_specificity": "3972 adults diagnosed with chronic hepatitis B.", "effective_dosage": "Not specified in the abstract.", "study_duration": "1 year of treatment.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:23.957129+00:00"}
{"study_id": 105434, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine factors predictive of postoperative biliary fistula (PBF) development and spontaneous closure in patients treated for hydatid liver disease, including the role of preoperative alanine aminotransferase levels.", "results_summary": "Preoperative high alanine aminotransferase levels (> 40 U/L) were a significant predictor of PBF development. The study did not focus on alanine's therapeutic effects but noted its association with PBF risk.", "population_specificity": "Patients with hydatid liver disease (median age 23, 77% male) undergoing surgical or percutaneous treatment.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:24.658115+00:00"}
{"study_id": 105436, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to assess the nationwide seroprevalence of HCV infection in South Korea and analyze associated biochemical markers, including alanine aminotransferase levels.", "results_summary": "The study found significantly higher levels of alanine aminotransferase in anti-HCV positive individuals compared to anti-HCV negative individuals, indicating potential liver involvement. No direct effects or outcomes related to alanine supplementation were assessed.", "population_specificity": "291,314 adults undergoing health check-ups in South Korea.", "effective_dosage": "Not available", "study_duration": "Not applicable (cross-sectional study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:25.044208+00:00"}
{"study_id": 105419, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the effects of clopidogrel plus aspirin versus aspirin alone on laboratory parameters, including alanine aminotransferase levels.", "results_summary": "The study found no significant differences in baseline alanine aminotransferase levels between the two groups, but did not report specific effects on alanine metabolism or function.", "population_specificity": "New users of clopidogrel plus aspirin (n=130) or aspirin alone (n=130) from a clinical data warehouse.", "effective_dosage": "Not specified for alanine (study focused on clopidogrel 75 mg/day and aspirin 100 mg/day).", "study_duration": "Up to 2 months after drug administration.", "interactions": "None mentioned for alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:25.579438+00:00"}
{"study_id": 105437, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the prevalence of baseline laboratory abnormalities, including alanine aminotransferase (ALT) levels, in patients with early arthritis and their impact on drug selection.", "results_summary": "Elevated ALT levels were found in 10% of patients, with 1.64% having contraindications to methotrexate therapy due to high ALT levels. The study did not assess the efficacy or safety of alanine itself.", "population_specificity": "Patients with early arthritis (1,393 participants, 1,018 women and 375 men).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:29.139901+00:00"}
{"study_id": 105438, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers evaluated the risk/benefit profile of new anticoagulants (NACs), including Alanine-related effects, compared to enoxaparin for venous thromboembolism (VTE) prophylaxis in major orthopedic surgery.", "results_summary": "Alanine amino transferase levels were significantly lower with 220 mg of dabigatran compared to enoxaparin, indicating a potential benefit in liver safety. The study did not focus on Alanine's direct efficacy but noted its role in safety markers.", "population_specificity": "Patients undergoing elective major orthopedic surgery.", "effective_dosage": "220 mg of dabigatran (Alanine-related effect noted).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:30.217714+00:00"}
{"study_id": 105440, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to examine the association between alanine aminotransferase (ALT) and atherogenic lipoprotein changes, and whether this relationship was influenced by insulin resistance, adiposity, glucose tolerance, and chronic inflammation.", "results_summary": "ALT was positively associated with several atherogenic lipoprotein changes, including triacylglycerols, LDL-to-HDL-cholesterol ratio, and apolipoprotein B, as well as specific NMR-measured lipoprotein subclasses. These associations persisted even after adjusting for metabolic factors, suggesting a partial but not complete explanation by insulin resistance and related conditions.", "population_specificity": "824 non-diabetic participants aged 40-69 years, excluding those with excessive alcohol intake or lipid-lowering medication use.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:32.280815+00:00"}
{"study_id": 105443, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to compare epidemiological data and initial management of newly diagnosed patients with persistent HBV or HCV infection, including the role of alanine aminotransferase (ALT) levels in decision-making for liver biopsy and antiviral therapy.", "results_summary": "The study found that HBV patients more frequently had normal ALT levels (65% vs. 29% in HCV patients) and that ALT was a major factor for performing liver biopsy or considering antiviral therapy in both groups. Despite its lack of sensitivity and specificity, ALT remains a pivotal decision-making tool for liver biopsy and antiviral therapy in HBV and HCV infections.", "population_specificity": "Newly diagnosed patients with persistent HBV (HBsAg positive) or HCV (detectable HCV RNA) infection in Belgium.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:33.520580+00:00"}
{"study_id": 105439, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to assess the safety, tolerability, and clinical effects of sebelipase alfa (a recombinant human lysosomal acid lipase) in patients with cholesteryl ester storage disease (CESD).", "results_summary": "Sebelipase alfa was well tolerated, with mostly mild adverse events unrelated to the treatment. It rapidly decreased serum transaminases and improved lipid profiles, with sustained effects during long-term dosing.", "population_specificity": "Nine patients with CESD, an inherited deficiency of lysosomal acid lipase.", "effective_dosage": "0.35, 1, or 3 mg\u00b7kg(-1) once weekly for four doses, then transitioning to every-other-week infusions (1 or 3 mg\u00b7kg(-1)).", "study_duration": "Initial study (LAL-CL01) involved four weekly infusions; extension study (LAL-CL04) included another four weekly doses followed by long-term every-other-week dosing (follow-up at least 12 weeks).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:33.644600+00:00"}
{"study_id": 105441, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the safety, pharmacokinetics, and recommended dose of S-1 combined with gefitinib in patients with pulmonary adenocarcinoma who had failed previous chemotherapy.", "results_summary": "The study found that the combination of S-1 and gefitinib was well tolerated, with a 50% response rate and median progression-free survival of 10.5 months. Elevated alanine aminotransferase (grade 3) was observed in one patient at dose level 2.", "population_specificity": "Patients with pulmonary adenocarcinoma who had failed previous chemotherapy.", "effective_dosage": "S-1 at 60 mg/m\u00b2 (level 1) and 80 mg/m\u00b2 (level 2) on days 1-14 every 21 days; gefitinib at 250 mg daily.", "study_duration": "21-day cycles (duration not explicitly stated).", "interactions": "No pharmacokinetic interaction between S-1 and gefitinib was detected.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:33.941968+00:00"}
{"study_id": 105444, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 70, "study_goal": "The researchers aimed to assess the efficacy and safety of bezafibrate in patients with advanced chronic hepatitis C, focusing on its effects on liver enzymes and cytokine expression.", "results_summary": "Bezafibrate significantly improved liver enzyme levels (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, \u03b3-glutamyltranspeptidase) and increased interferon-\u03b3 expression, but had no significant effect on viral load or tumor necrosis factor-\u03b1 and interleukin-6 levels.", "population_specificity": "Patients with advanced chronic hepatitis C (n=34, with a subpopulation of n=8 for cytokine analysis).", "effective_dosage": "400 mg/day (oral).", "study_duration": "Mean treatment duration of 19 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:34.111002+00:00"}
{"study_id": 105442, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate cases of drug-induced liver injury (DILI) associated with TNF-\u03b1 antagonists, including the role of alanine aminotransferase levels in assessing liver damage.", "results_summary": "The study found that TNF-\u03b1 antagonists, particularly infliximab, were associated with DILI, often presenting with autoimmune features and elevated alanine aminotransferase levels. Most cases improved after discontinuation of the drug, though some required corticosteroid therapy.", "population_specificity": "Patients in the U.S. DILI Network database (2003-2011) and additional cases from PubMed, totaling 34 subjects with DILI linked to TNF-\u03b1 antagonists.", "effective_dosage": "Not specified", "study_duration": "Median latency of 13 weeks (range: 2-104 weeks)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:34.116144+00:00"}
{"study_id": 105445, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy of erythromycin in treating hepatic encephalopathy (HE) and its impact on alanine aminotransferase levels.", "results_summary": "The erythromycin group showed a significant reduction in hospitalization stay and alanine aminotransferase levels compared to the neomycin group. Hospitalization duration was positively correlated with C-reactive protein levels before and after treatment.", "population_specificity": "Adult patients with hepatic encephalopathy and hepatic cirrhosis admitted to the hospital.", "effective_dosage": "Erythromycin 250 mg orally QID.", "study_duration": "Until hospital discharge or prescription of another antibiotic.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:37.820778+00:00"}
{"study_id": 105446, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the treatment outcomes of clevudine versus entecavir in antiviral-naive patients with chronic hepatitis B, focusing on biochemical, virologic, and serologic responses.", "results_summary": "Clevudine showed similar efficacy to entecavir in serum ALT normalization, HBV DNA reduction, and HBeAg seroconversion, but had higher rates of virologic breakthrough with genotypic mutations.", "population_specificity": "Antiviral-naive patients with chronic hepatitis B.", "effective_dosage": "Clevudine 30 mg/d; entecavir 0.5 mg/d.", "study_duration": "96 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:39.394554+00:00"}
{"study_id": 105447, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were attempting to evaluate the relationship between voriconazole dose and serum concentrations in obese and overweight immunocompromised patients, including the impact on alanine aminotransferase levels.", "results_summary": "Higher voriconazole concentrations were associated with elevated alanine aminotransferase levels (>3x upper limit of normal). Patients with random concentrations \u22652 mg/L had higher response rates (50%) compared to those with lower concentrations (33%).", "population_specificity": "92 immunocompromised patients with hematologic malignancies and/or hematopoietic stem cell transplants.", "effective_dosage": "Median daily doses were 640 mg for BMI \u226525 kg/m\u00b2 and 400 mg for BMI <25 kg/m\u00b2.", "study_duration": "Data collected from 2005-2010 (exact intervention duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:41.558493+00:00"}
{"study_id": 105448, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to differentiate the node-first presentation of Kawasaki disease (NFKD) from bacterial cervical lymphadenitis (BCL) and typical Kawasaki disease (KD) by comparing clinical, laboratory, and imaging characteristics.", "results_summary": "The study found that patients with NFKD had higher alanine transaminase levels compared to those with BCL, along with other distinct laboratory and imaging features. NFKD patients also exhibited more severe inflammation but similar rates of coronary artery abnormalities and treatment resistance compared to typical KD patients.", "population_specificity": "Pediatric patients hospitalized for NFKD, BCL, or typical KD.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:42.106276+00:00"}
{"study_id": 105450, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare the effectiveness of (68)Ga-DOTANOC and (68)Ga-DOTATATE PET/CT in detecting lesions in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and evaluate the clinical impact of (68)Ga-DOTANOC.", "results_summary": "(68)Ga-DOTANOC PET demonstrated a higher lesion detection rate (93.5%) compared to (68)Ga-DOTATATE (85.5%), particularly for liver metastases, and influenced treatment decisions in 17% of patients.", "population_specificity": "Eighteen patients with biopsy-proven GEP-NETs (4 low-grade, 7 intermediate-grade, 7 high-grade).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:42.931465+00:00"}
{"study_id": 105451, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate whether current Chinese guidelines for Nevirapine (NVP) use, which are based on CD4 cell count thresholds, are appropriate in predicting hepatotoxicity risk.", "results_summary": "The study found that hepatotoxicity was common in patients with CD4 counts >250 cells/\u03bcL, with 36.1% developing hepatotoxicity and 7.7% experiencing severe hepatotoxicity. CD4 counts >250 cells/\u03bcL were an independent predictor of hepatotoxicity in both men and women.", "population_specificity": "566 antiretroviral therapy-naive Chinese patients (men and women) receiving NVP-containing therapy.", "effective_dosage": "Not specified", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:43.003740+00:00"}
{"study_id": 105449, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare clinical, serologic, and virologic features between children carrying HBsAg-mutant HBV and wild-type HBV, focusing on hepatitis activity and outcomes.", "results_summary": "Children with HBsAg-mutant HBV showed higher ALT levels, earlier HBeAg seroconversion, and lower viremic states compared to wild-type HBV carriers. No cirrhosis or HCC developed in the study group, but HBsAg-mutant HBV was detected in some HCC cases.", "population_specificity": "HBsAg-positive children aged 0.5-18.4 years who did not respond to postnatal immunoprophylaxis.", "effective_dosage": "Not available", "study_duration": "Mean follow-up of 8.5 years (range 1-22.8 years)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:43.005101+00:00"}
{"study_id": 105452, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were investigating the efficacy and safety of bevacizumab, not alanine, for the treatment of advanced hepatocellular carcinoma (HCC).", "results_summary": "The study found that bevacizumab showed promise as an effective and tolerable treatment for advanced HCC, with disease control rates ranging from 51.1% to 76.9% and response rates up to 23.7%. Common toxicities included increased liver enzymes, fatigue, and hypertension.", "population_specificity": "Patients with advanced or unresectable hepatocellular carcinoma (HCC).", "effective_dosage": "Not mentioned (focus was on bevacizumab, not alanine).", "study_duration": "Not mentioned (focus was on bevacizumab, not alanine).", "interactions": "None mentioned (focus was on bevacizumab, not alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:43.341798+00:00"}
{"study_id": 105453, "supplement_id": 863, "safety_score": "30", "efficacy_score": 40, "quality_score": 75, "study_goal": "The researchers were evaluating the safety and efficacy of lapatinib plus pazopanib therapy versus lapatinib monotherapy in HER2-positive advanced/metastatic breast cancer patients, including monitoring alanine aminotransferase elevations as a safety measure.", "results_summary": "The study found elevated alanine aminotransferase levels (>5 times the upper limit of normal) in 18% of combination therapy patients in Cohort 1 and 20% in Cohort 2, indicating potential liver toxicity. The combination therapy did not significantly improve progressive disease rates but showed a higher response rate compared to monotherapy.", "population_specificity": "Patients with HER2-positive advanced/metastatic breast cancer.", "effective_dosage": "Not specified for alanine (study focused on lapatinib and pazopanib dosages).", "study_duration": "12 weeks (primary endpoint assessment).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:47.531120+00:00"}
{"study_id": 105454, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effects of entecavir therapy on NK cell phenotype and function in chronic HBV patients, including associations with alanine aminotransferase (ALT) levels.", "results_summary": "The study found that chronic HBV patients had altered NK cell profiles compared to healthy controls, with entecavir treatment normalizing ALT levels and improving NK cell-mediated immunity. There was a positive correlation between NK cell receptor expression (NKG2D+ and NKP30+) and serum ALT levels.", "population_specificity": "18 chronic HBV patients and 14 healthy controls.", "effective_dosage": "10 mg/day, orally.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:49.104882+00:00"}
{"study_id": 105455, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine (not Alanine) compared to placebo in postmenopausal women.", "results_summary": "The study found no increased risk of cardiovascular, cerebrovascular, or hepatic events with desvenlafaxine 100 mg/day compared to placebo. One cardiovascular event occurred in the placebo group, and one cerebrovascular event occurred in the desvenlafaxine group, with no significant excess risk for either treatment.", "population_specificity": "Healthy postmenopausal women seeking treatment for vasomotor symptoms.", "effective_dosage": "100 mg/day of desvenlafaxine.", "study_duration": "1 year.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:50.581044+00:00"}
{"study_id": 105456, "supplement_id": 863, "safety_score": "70", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to assess the safety and efficacy of teriflunomide, which affects alanine aminotransferase levels, as a disease-modifying therapy for multiple sclerosis.", "results_summary": "Teriflunomide showed potential benefits in reducing relapse rates and was generally safe in the short term, though elevated alanine aminotransferase levels were among the reported adverse events. The evidence was limited due to study quality and attrition bias.", "population_specificity": "Adult patients with relapsing forms of multiple sclerosis (RRMS, SPMS with relapse, PRMS) and an EDSS score \u2264 5.5.", "effective_dosage": "7 mg and 14 mg (alone or with add-on IFN-\u03b2).", "study_duration": "At least one year.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:51.559702+00:00"}
{"study_id": 105460, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to assess the safety and initial efficacy of umbilical cord-derived mesenchymal stem cell (UC-MSC) transfusions for treating acute-on-chronic liver failure (ACLF) associated with hepatitis B virus (HBV) infection.", "results_summary": "UC-MSC transfusions significantly improved survival rates, liver function markers (e.g., reduced bilirubin and alanine aminotransferase levels), and increased serum albumin and platelet counts without significant side effects.", "population_specificity": "43 ACLF patients associated with HBV infection (24 treated with UC-MSCs, 19 controls).", "effective_dosage": "UC-MSC therapy administered three times at 4-week intervals.", "study_duration": "12 weeks (three doses at 4-week intervals), with follow-up periods of 48 or 72 weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:53.104139+00:00"}
{"study_id": 105459, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether dietary supplementation with docosahexaenoic acid (DHA) could reduce liver fat content in children with non-alcoholic fatty liver disease (NAFLD), as measured by changes in alanine transaminase (ALT) and other markers.", "results_summary": "DHA supplementation at both 250 mg/day and 500 mg/day significantly reduced liver steatosis severity, lowered triglycerides, and decreased ALT levels from month 12 onward, with similar efficacy between the two doses. HOMA-IR improved in the 250 mg/day group at months 6 and 12.", "population_specificity": "60 children with NAFLD (20 per group).", "effective_dosage": "250 mg/day and 500 mg/day of DHA.", "study_duration": "24 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:53.176611+00:00"}
{"study_id": 105458, "supplement_id": 863, "safety_score": "65", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the incidence of elevated alanine transferase (ALT) levels (>2\u00d7 ULN) in rheumatoid arthritis patients treated with methotrexate (MTX) and identify predictors of such elevations.", "results_summary": "The study found an incidence rate of 6.3 per 100 patient-years for ALT >2\u00d7 ULN, with ACPA positivity and baseline ALT >1\u00d7 ULN as independent predictors. Patients with elevated ALT had higher mean MTX dosages, while those without used more concomitant antirheumatic drugs.", "population_specificity": "508 recent-onset rheumatoid arthritis (RA) patients from the BeSt study.", "effective_dosage": "Not specified (dynamic dosing strategy).", "study_duration": "Total duration on MTX was 1,416 patient-years (average ~2.8 years per patient).", "interactions": "Concomitant disease-modifying antirheumatic drugs were noted.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:53.691877+00:00"}
{"study_id": 105457, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate whether Chlorella vulgaris supplementation, in combination with metformin and vitamin E, could improve outcomes in patients with non-alcoholic fatty liver disease (NAFLD), including effects on serum alanine aminotransferase (ALT) levels.", "results_summary": "The study found that the Chlorella group showed significant reductions in serum ALT and AST levels, triglycerides, and improved insulin sensitivity, while the metformin group primarily improved cholesterol and blood sugar markers. Borderline significant reductions in insulin and fasting blood sugar were also noted in the Chlorella group.", "population_specificity": "76 individuals with NAFLD.", "effective_dosage": "Chlorella vulgaris extract (1200 mg/day) + metformin (750 mg/day) + vitamin E (200 mg/day) for the Chlorella group; metformin (1250 mg/day) + vitamin E (200 mg/day) for the control group.", "study_duration": "3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:53.989240+00:00"}
{"study_id": 105461, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare the effects of LY2605541 (a novel long-acting basal insulin) versus insulin glargine on daily mean blood glucose in patients with type 1 diabetes.", "results_summary": "LY2605541 demonstrated superior glycemic control compared to insulin glargine, with reduced fasting blood glucose variability, A1C, and weight, but higher total hypoglycemia rates. Adverse events were similar, though gastrointestinal-related events were more frequent with LY2605541.", "population_specificity": "137 patients with type 1 diabetes.", "effective_dosage": "Once-daily basal insulin (specific dosage not provided).", "study_duration": "8 weeks per treatment phase (total 16 weeks with crossover).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:55.993235+00:00"}
{"study_id": 105462, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study did not aim to evaluate Alanine specifically; it focused on comparing the effects of lopinavir-ritonavir-based ART versus NNRTI-based ART on malaria incidence in HIV-infected children.", "results_summary": "The study did not report findings related to Alanine's effects. Elevated alanine aminotransferase levels were noted more frequently in the NNRTI group, but this was not the primary focus of the research.", "population_specificity": "HIV-infected children aged 2 months to 5 years.", "effective_dosage": "Not mentioned for Alanine.", "study_duration": "Follow-up ranged from 6 months to 2 years.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:57.053370+00:00"}
{"study_id": 105464, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the accuracy of non-invasive scoring systems (FIB-4 index, NAFLD fibrosis score, BARD score, and AST/ALT ratio) in predicting liver fibrosis severity in NAFLD patients with normal ALT levels.", "results_summary": "The study found that resetting cutoff values for these scoring systems improved their sensitivity, specificity, and negative predictive value for detecting advanced fibrosis, potentially reducing the need for liver biopsies by 51.9% to 66.4%. The FIB-4 index and NAFLD fibrosis score were particularly effective (AUROC >0.8).", "population_specificity": "1,102 liver-biopsy-confirmed NAFLD patients, including 235 with normal ALT levels.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:00.244024+00:00"}
{"study_id": 105463, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the effectiveness of liver transplantation (LT) as a treatment for Primary Hyperoxaluria Type-1 (PH1), a disorder linked to impaired alanine-glyoxylate aminotransferase activity.", "results_summary": "The study found that LT could be curative for PH1 patients if performed preemptively, but delayed diagnosis often led to end-stage renal disease (ESRD) and complications. One patient died of sepsis, while the other two showed positive outcomes post-LT, with one avoiding ESRD and another successfully withdrawing from hemodialysis after combined LT and kidney transplantation.", "population_specificity": "Three PH1 patients with varying disease progression, including two with delayed diagnosis leading to ESRD.", "effective_dosage": "Not mentioned", "study_duration": "Follow-up ranged from 8 months to 8 years post-LT.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:00.283983+00:00"}
{"study_id": 105466, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the role of alanine aminotransferase (ALT) as an indirect biomarker for monitoring recent alcohol intake and alcohol-induced liver damage.", "results_summary": "The study found that ALT, along with other liver enzymes, is commonly used as an indicator of alcohol-induced liver damage but has moderate specificity due to non-alcohol-related elevations. Direct ethanol metabolites were noted to offer higher specificity and sensitivity compared to indirect markers like ALT.", "population_specificity": "Not specified (general clinical or forensic context implied).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:00.583728+00:00"}
{"study_id": 105468, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare clinical characteristics and imaging findings in patients with acute cholangitis, with and without biliary dilatation, focusing on alanine aminotransferase (ALT) levels as a marker.", "results_summary": "Patients without biliary dilatation had higher median ALT levels compared to those with biliary dilatation, suggesting a potential role of ALT in differentiating these groups. The study did not evaluate Alanine as a supplement but rather as a biomarker in cholangitis.", "population_specificity": "93 patients diagnosed with acute cholangitis (17 without biliary dilatation, 76 with biliary dilatation).", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:02.434393+00:00"}
{"study_id": 105465, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 90, "study_goal": "The researchers aimed to compare the effects of telbivudine (LDT) and entecavir (ETV) on HBeAg-positive chronic hepatitis B, including outcomes related to alanine aminotransferase (ALT) normalization.", "results_summary": "The study found that LDT and ETV had similar rates of HBV DNA undetectability and ALT normalization, but LDT showed better serological response (HBeAg loss and seroconversion) at certain time points. However, LDT had a higher rate of drug-resistance and increased creatine kinase compared to ETV.", "population_specificity": "HBeAg-positive chronic hepatitis B patients (3925 participants across 13 trials).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Various durations from 4 weeks to 72 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:03.311050+00:00"}
{"study_id": 105467, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the effect of metformin on metabolic risk factors, including alanine aminotransferase (ALT), in obese children and young people with hyperinsulinemia or glucose intolerance.", "results_summary": "Metformin significantly improved ALT levels by 19% at 3 months, indicating a beneficial effect on liver function, alongside reductions in BMI-SDS and fasting glucose. These improvements were sustained for BMI-SDS at 6 months.", "population_specificity": "Obese children and young people (ages 8-18, mean 13.7) with hyperinsulinemia, impaired fasting glucose, or impaired glucose tolerance, predominantly female (67.5%) and postpubertal (65.6%).", "effective_dosage": "1 g in the morning and 500 mg in the evening.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:04.442937+00:00"}
{"study_id": 105469, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the suitability of posaconazole as salvage therapy for invasive aspergillosis in patients previously treated with voriconazole, not specifically to evaluate Alanine.", "results_summary": "The study found that posaconazole was safe and effective as salvage therapy, with a 72.2% success rate and no discontinuations due to adverse events. Liver enzyme levels decreased during posaconazole treatment compared to voriconazole.", "population_specificity": "Haematological patients with invasive aspergillosis from four German hospitals.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Evaluated at 30 and 60 days post-posaconazole initiation.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:04.558381+00:00"}
{"study_id": 105470, "supplement_id": 863, "safety_score": "100", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the long-term efficacy and tolerability of entecavir (ETV) 0.5 mg daily in treatment-naive HBeAg-positive chronic hepatitis B patients in routine clinical settings.", "results_summary": "The study found that ETV was highly tolerable and effective at suppressing hepatitis B viremia, with complete viral suppression rates increasing over time (41% at 12 months, 85% at 36 months). However, HBeAg seroconversion rates were lower than in registration trials (4.8% at 12 months, 30% at 36 months).", "population_specificity": "Treatment-naive HBeAg-positive chronic hepatitis B patients in the USA.", "effective_dosage": "0.5 mg daily", "study_duration": "Median treatment duration was 18 months (range 6-60 months).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:06.377449+00:00"}
{"study_id": 105473, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and tolerability of ribavirin and peginterferon combination therapy for chronic HCV infection in patients with coagulation disorders compared to those without.", "results_summary": "The study found no significant difference in sustained virological response rates between patients with and without coagulation disorders (65.2% vs. 47.8%). Alanine aminotransferase levels were significantly associated with treatment response, but coagulation disorders did not affect outcomes.", "population_specificity": "Chronic hepatitis C patients with (n=23) and without (n=203) coagulation disorders.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:08.438154+00:00"}
{"study_id": 105471, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to differentiate between inactive HBV carriers and patients with HBeAg-negative chronic hepatitis B with transient remission, focusing on management strategies for HBsAg-positive patients with normal alanine aminotransferase levels.", "results_summary": "The study highlights the challenge of distinguishing inactive HBV carriers from patients with chronic hepatitis B in remission, emphasizing the importance of careful assessment and follow-up due to differing prognoses and risks of complications. It provides evidence-based suggestions for clinical management, including lifestyle advice, vaccination, biopsy indications, and treatment options.", "population_specificity": "HBsAg-positive/HBeAg-negative patients with normal alanine aminotransferase levels.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:08.852562+00:00"}
{"study_id": 105472, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 73, "quality_score": 65, "study_goal": "The researchers aimed to evaluate non-invasive liver fibrosis tests, including alanine aminotransferase (ALT), as predictors of fibrosis and non-sustained viral response in chronic hepatitis C patients.", "results_summary": "Non-invasive liver fibrosis tests, including ALT-related measures, were found to be highly effective in predicting non-sustained viral response, particularly with the age-platelet index (Accuracy=73%, OR=6.93). Multivariate analysis showed strong relationships between non-sustained viral response and factors like viral load and age-platelet index.", "population_specificity": "Chronic hepatitis C naive patients at \u0130zmir Atat\u00fcrk Training and Research Hospital.", "effective_dosage": "Not specified", "study_duration": "Retrospective study period from July 2008 to August 2010", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:09.456557+00:00"}
{"study_id": 105475, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "To investigate whether parenteral nutrition with omega-3 fatty acids improves liver function and clinical outcomes in patients undergoing liver transplantation, as measured by alanine aminotransferase levels and other markers.", "results_summary": "Omega-3 fatty acid supplementation significantly reduced alanine aminotransferase levels and prothrombin time, improved hepatic cell injury, decreased hospital stay, and lowered infection rates compared to standard PN. One-year mortality was lower in the omega-3 group (3.1% vs. 9.1%).", "population_specificity": "Patients with end-stage liver disease or hepatic cellular carcinoma undergoing orthotopic liver transplantation.", "effective_dosage": "Not specified (omega-3 fish oil lipid emulsion replaced part of standard lipid emulsion).", "study_duration": "7 days post-surgery.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:12.183605+00:00"}
{"study_id": 105476, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the cost-effectiveness of different chronic hepatitis B (CHB) screening and treatment guidelines, including the role of alanine aminotransferase levels in individualized treatment.", "results_summary": "The study found that using the B positive algorithm for CHB management was more cost-effective than current standard care or HCC screening, with drug treatment being the largest expenditure. The AASLD guidelines were the least costly, while EASL and the US Expert Group guidelines increased costs by 46%.", "population_specificity": "Australians born in countries with high CHB prevalence.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:12.537163+00:00"}
{"study_id": 105477, "supplement_id": 863, "safety_score": "45", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and efficacy of mipomersen, an antisense oligonucleotide, in reducing LDL-C and other atherogenic lipoproteins in patients with severe hypercholesterolemia.", "results_summary": "Mipomersen significantly reduced LDL-C by 36% and other atherogenic lipoproteins, but adverse events included injection site reactions, flu-like symptoms, and hepatic effects like elevated alanine transaminase. Serious adverse events and discontinuations were more frequent in the mipomersen group compared to placebo.", "population_specificity": "Patients \u226518 years with severe hypercholesterolemia (LDL-C \u22657.8 mmol/L or LDL-C \u22655.1 mmol/L plus CHD) on maximally tolerated lipid-lowering therapy.", "effective_dosage": "200 mg weekly subcutaneous injections.", "study_duration": "26 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:13.902353+00:00"}
{"study_id": 105478, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 30, "study_goal": "The researchers aimed to highlight the importance of considering acute hepatitis C as a cause of elevated alanine aminotransferase in HIV-infected men who have sex with men.", "results_summary": "The study reported a case of an HIV-infected adult with elevated alanine aminotransferase due to acute hepatitis C, which improved with outpatient treatment. It emphasized the higher risk of chronic hepatitis C progression in HIV-coinfected patients.", "population_specificity": "HIV-infected men who have sex with men.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:14.670939+00:00"}
{"study_id": 105474, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether HCV genotype 1 subtypes 1a and 1b respond differently to treatment with PEG-IFN plus ribavirin, focusing on factors like alanine aminotransferase (ALT) levels as predictors of sustained virological response (SVR).", "results_summary": "The study found that lower alanine aminotransferase (ALT) levels (<100 IU/ml) were an independent predictor of higher SVR rates (OR: 2.1). Subtype 1a patients had a higher SVR rate (55%) compared to subtype 1b (43%).", "population_specificity": "388 treatment-na\u00efve patients chronically infected with hepatitis C genotype 1 (subtypes 1a and 1b).", "effective_dosage": "Ribavirin (1000-1200 mg/day) combined with weekly PEG-IFN \u03b1-2a or PEG-IFN \u03b1-2b.", "study_duration": "48 weeks of treatment, with follow-up 24 weeks post-treatment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:14.949691+00:00"}
{"study_id": 105479, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to assess serum antioxidant-oxidant (Redox) balance in chronic hepatitis C virus (CHC) patients before and after antiviral therapy, not specifically focused on Alanine.", "results_summary": "The study found elevated oxidative stress markers (e.g., MDA) and reduced antioxidants in CHC patients, with responders showing lower MDA levels. Alanine aminotransferase (ALT) levels were higher in CHC patients but not directly linked to redox parameters.", "population_specificity": "50 biopsy-proven CHC patients and 15 healthy controls.", "effective_dosage": "Not specified for Alanine.", "study_duration": "25 weeks post-antiviral therapy.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:17.320824+00:00"}
{"study_id": 105480, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 90, "study_goal": "The researchers aimed to investigate the incidence and risk factors of severe liver injury in HIV-infected children receiving long-term isoniazid preventive therapy (IPT), with a focus on alanine transaminase (ALT) levels as a marker of liver injury.", "results_summary": "The study found that IPT-related severe liver injury occurred in 1.7% of children (5/297), with no cases of hepatic failure. Most liver injuries were linked to viral hepatitis or antiretroviral therapy rather than IPT, and all surviving children later tolerated IPT.", "population_specificity": "HIV-infected children aged \u22658 weeks in two paediatric hospitals in Cape Town, South Africa.", "effective_dosage": "Daily or thrice weekly IPT (specific dosage not detailed).", "study_duration": "Long-term (median follow-up not specified, but ALT was measured at baseline and 6-monthly).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:18.987949+00:00"}
{"study_id": 105481, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to study the clinical features and risk factors of interstitial lung disease (ILD) in Chinese patients with clinically amyopathic dermatomyositis (CADM), including the role of alanine aminotransferase levels.", "results_summary": "The study found that alanine aminotransferase levels were higher in CADM patients with ILD compared to those without ILD, suggesting a potential biomarker role. No direct effects or therapeutic outcomes of alanine were assessed.", "population_specificity": "Chinese Han patients with clinically amyopathic dermatomyositis (n=41).", "effective_dosage": "Not available", "study_duration": "Retrospective analysis from August 2008 to 2011 (exact intervention duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:19.815643+00:00"}
{"study_id": 105482, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to determine the maximum tolerated dose of everolimus in advanced hepatocellular carcinoma patients, not specifically to evaluate Alanine.", "results_summary": "The study reported grade 3/4 adverse events including alanine transaminase (ALT) elevation, but did not focus on Alanine's effects.", "population_specificity": "Patients with locally advanced or metastatic hepatocellular carcinoma (Child-Pugh class A or B).", "effective_dosage": "Not applicable (study focused on everolimus, not Alanine).", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:20.142355+00:00"}
{"study_id": 105483, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to determine whether elevated alanine transaminase levels are associated with an increased risk of incident atrial fibrillation (AF) in a community-based population.", "results_summary": "Elevated alanine transaminase levels were significantly associated with a greater risk of incident AF (hazard ratio 1.19, p = 0.002), though the improvement in AF prediction when added to known risk factors was subtle.", "population_specificity": "3,744 participants (mean age 65 \u00b1 10 years, 56.8% women) from the Framingham Heart Study Original and Offspring cohorts, free of clinical heart failure.", "effective_dosage": "Not specified", "study_duration": "Up to 10 years of follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:21.748749+00:00"}
{"study_id": 105486, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to examine hepatic enzyme test results, including alanine aminotransferase (ALT), in pregnant women maintained on methadone or buprenorphine.", "results_summary": "ALT levels decreased across pregnancy trimesters and rose slightly postpartum. HCV-positive subjects had higher transaminases than HCV-negative subjects, but neither methadone nor buprenorphine showed adverse hepatic effects.", "population_specificity": "175 opioid-dependent pregnant women enrolled in the MOTHER study.", "effective_dosage": "Not specified", "study_duration": "Throughout pregnancy and once postpartum (exact duration not specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:23.117924+00:00"}
{"study_id": 105485, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the predictive values of liver enzymes, including alanine aminotransferase (ALT), for hepatocellular carcinoma (HCC) risk in HBV patients.", "results_summary": "Elevated ALT levels were associated with higher HCC incidence rates in HBV patients, though GGT showed the strongest predictive value. The study found a cumulative effect between baseline GGT and ALP in increasing HCC risk.", "population_specificity": "588 Korean American HBV patients", "effective_dosage": "Not specified", "study_duration": "Median follow-up of 7.5 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:23.517533+00:00"}
{"study_id": 105484, "supplement_id": 863, "safety_score": "80", "efficacy_score": 95, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety and efficacy of a pyronaridine-artesunate pediatric granule formulation compared to artemether-lumefantrine for treating uncomplicated Plasmodium falciparum malaria in children.", "results_summary": "The pyronaridine-artesunate formulation was highly efficacious (97.1% PCR-corrected day-28 ACPR) and non-inferior to artemether-lumefantrine. Safety profiles were similar, with a lower incidence of drug-related adverse events in the pyronaridine-artesunate group (37.2% vs. 44.4%).", "population_specificity": "Children aged \u226412 years, bodyweight \u22655 to <25 kg, with uncomplicated P. falciparum malaria.", "effective_dosage": "Pyronaridine-artesunate granules (60/20 mg) once daily or artemether-lumefantrine crushed tablets (20/120 mg) twice daily, dosed by bodyweight.", "study_duration": "3 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:24.400789+00:00"}
{"study_id": 105487, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the hepatoprotective potential of Feronia limonia stem bark (FSB) extracts, including their effects on alanine aminotransferase (ALT) levels in HepG2 cells and rats.", "results_summary": "FSB extracts, particularly the methanolic extract (FSB-7), showed hepatoprotective effects by reducing hepatic damage, preserving cellular antioxidants, and minimizing liver histoarchitecture distortion in CCl4-treated rats, comparable to silymarin.", "population_specificity": "HepG2 cells and rats treated with CCl4.", "effective_dosage": "200 or 400 mg/kg bodyweight of FSB-7, 25 mg/kg bodyweight of silymarin.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:27.105712+00:00"}
{"study_id": 105488, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to determine the risk of hepatotoxicity associated with the use of tyrosine kinase inhibitors (TKIs), including effects on alanine transaminase levels.", "results_summary": "The study found a significantly increased risk of high-grade hepatotoxicity with TKI use, including elevated alanine transaminase levels (Pooled OR 5.22, 95% CI 2.88-9.46). The odds of all-grades hepatotoxicity were also higher with TKIs compared to controls.", "population_specificity": "Patients in randomized, double-blind, placebo-controlled phase 2 or phase 3 human trials involving TKIs.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:28.256723+00:00"}
{"study_id": 105489, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to compare the efficacy and safety of once-daily darunavir/ritonavir (DRV/r) versus lopinavir/ritonavir (LPV/r) in treatment-na\u00efve HIV-1-infected adults, not specifically focusing on Alanine.", "results_summary": "The study found that DRV/r was noninferior and statistically superior in virological response to LPV/r, with fewer adverse events and better gastrointestinal tolerance. Changes in alanine aminotransferase levels were similar between the two groups.", "population_specificity": "Treatment-na\u00efve HIV-1-infected adults", "effective_dosage": "Not applicable (study did not focus on Alanine)", "study_duration": "192 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:29.060898+00:00"}
{"study_id": 105490, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the antiviral efficacy of entecavir (ETV) and adefovir dipivoxil (ADV) in treating chronic hepatitis B (CHB) patients, including effects on serum alanine aminotransferase (ALT) levels.", "results_summary": "The study found that both ETV and ADV significantly decreased serum ALT levels by 12 weeks, with no difference between treatments. ETV showed superior efficacy in HBeAg seroconversion at 24 weeks compared to ADV.", "population_specificity": "72 ETV-treated and 66 ADV-treated chronic hepatitis B (CHB) patients.", "effective_dosage": "Not specified", "study_duration": "96 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:30.055227+00:00"}
{"study_id": 105491, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to characterize the dynamic and energetic determinants of PHD finger recognition of unmodified histone H3 peptides, focusing on the AIRE-PHD1/H3K4me0 complex and alanine mutants.", "results_summary": "The study found that binding free energy calculations for AIRE-PHD1/H3K4me0 complexes, including alanine mutants, agreed well with experimental data, revealing that recognition relies on electrostatic and polar solvation energy compensation and is stabilized by non-polar interactions.", "population_specificity": "Not applicable (computational study)", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:30.456506+00:00"}
{"study_id": 105492, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the therapeutic efficacy of vitamin E in reducing oxidative stress and improving outcomes in patients with nonalcoholic steatohepatitis (NASH), with a focus on its impact on alanine aminotransferase levels.", "results_summary": "Vitamin E showed significant improvement in steatosis, inflammation, and ballooning in adult NASH patients without diabetes or cirrhosis, but did not sustain alanine aminotransferase reduction in children.", "population_specificity": "Adult patients with aggressive NASH (without diabetes or cirrhosis) and children with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:31.736939+00:00"}
{"study_id": 105493, "supplement_id": 863, "safety_score": "30", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether high-dose multivitamin supplementation, including alanine-related effects (specifically ALT elevations), was safe and effective in reducing HIV disease progression or death in patients initiating HAART.", "results_summary": "High-dose multivitamin supplementation did not reduce HIV disease progression or death but increased the risk of ALT elevations compared to standard-dose supplementation. No significant effects were observed on CD4 count, viral load, BMI, or hemoglobin levels.", "population_specificity": "3418 HIV-positive patients initiating HAART in Dar es Salaam, Tanzania.", "effective_dosage": "Daily oral supplements of vitamin B complex, vitamin C, and vitamin E at high levels or standard levels of the recommended dietary allowance (specific amounts not detailed in the abstract).", "study_duration": "24 months (median follow-up of 15 months due to early termination).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:34.511242+00:00"}
{"study_id": 105495, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate potential pharmacokinetic-pharmacodynamic relationships of bosutinib, including its effects on alanine aminotransferase levels, in patients with chronic phase chronic myeloid leukemia.", "results_summary": "The study found no evidence of an exposure-response relationship for elevated alanine aminotransferases, indicating that bosutinib exposure did not significantly affect alanine aminotransferase levels.", "population_specificity": "Patients with chronic phase chronic myeloid leukemia (aged 18-91 years; mean weight, 75 kg; 54% male).", "effective_dosage": "500 mg/day", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:35.183864+00:00"}
{"study_id": 105494, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the safety, tolerability, antiviral activity, and pharmacokinetics of IDX184, a liver-targeted prodrug of 2'-methylguanosine monophosphate, in treatment-na\u00efve patients with genotype-1 chronic HCV infection.", "results_summary": "IDX184 demonstrated significant antiviral activity with dose-related reductions in HCV RNA levels, particularly at doses \u226575 mg, and no serious adverse events or safety-related discontinuations were reported. Serum ALT levels decreased, especially at higher doses, but viral load and ALT levels returned to near baseline post-treatment.", "population_specificity": "Treatment-na\u00efve patients with genotype-1 chronic HCV infection, baseline HCV RNA \u22655 log(10) IU/ml, ALT \u22642.5\u00d7 upper limit of normal, and compensated liver disease.", "effective_dosage": "25, 50, 75, and 100 mg once daily.", "study_duration": "3 days of treatment with a 14-day follow-up.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:36.133186+00:00"}
{"study_id": 105496, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effect of etanercept versus PUVA therapy on hepatic fibrosis risk in patients with psoriasis, metabolic syndrome, and NAFLD, focusing on markers like AST/ALT ratio and insulin resistance.", "results_summary": "Etanercept significantly reduced AST/ALT ratio, CRP levels, fasting insulin, and HOMA index while increasing QUICKI, suggesting it may lower hepatic fibrosis risk more effectively than PUVA therapy. The effect was linked to anti-inflammatory and glucose homeostatic properties.", "population_specificity": "Patients with chronic moderate-to-severe plaque-type psoriasis, metabolic syndrome, and NAFLD diagnosed by ultrasonography.", "effective_dosage": "Not specified", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:37.268140+00:00"}
{"study_id": 105497, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the long-term safety and efficacy of tenofovir, entecavir, and lamivudine in patients with chronic HBV infection and cirrhosis.", "results_summary": "Tenofovir and entecavir showed higher efficacy in achieving HBV DNA suppression and alanine aminotransferase normalization compared to lamivudine, with similar safety profiles and fewer treatment changes required.", "population_specificity": "Adult patients with chronic HBV infection and compensated or decompensated cirrhosis.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Follow-up durations were 21.4 \u00b1 9.7 months for tenofovir, 24.0 \u00b1 13.3 months for entecavir, and 36.5 \u00b1 24.1 months for lamivudine.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:38.032904+00:00"}
{"study_id": 105498, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers evaluated the safety and efficacy of mipomersen, an apolipoprotein B synthesis inhibitor, in reducing LDL-C and other lipoproteins in HeFH patients with coronary artery disease.", "results_summary": "Mipomersen significantly reduced LDL-C (-28.0%), apolipoprotein B (-26.3%), total cholesterol (-19.4%), and lipoprotein(a) (-21.1%) compared to placebo. Adverse events included injection site reactions, influenza-like symptoms, and increased hepatic fat content (median 4.9%).", "population_specificity": "Patients with heterozygous familial hypercholesterolemia (HeFH) and coronary artery disease on maximally tolerated statin therapy.", "effective_dosage": "200 mg weekly subcutaneous injection.", "study_duration": "26 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:38.760211+00:00"}
{"study_id": 105499, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify factors associated with outcomes (death or survival) in patients with acute liver failure (ALF) admitted to the ICU, including the role of alanine aminotransferase levels.", "results_summary": "The study found that serum alanine aminotransferase levels were similar between survivors and nonsurvivors, indicating it was not a significant predictor of outcome in ALF. Higher SOFA scores, severe encephalopathy, and prolonged prothrombin time were associated with mortality.", "population_specificity": "Patients with acute liver failure admitted to the ICU (median age 19 years, range 3-65).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:39.619633+00:00"}
{"study_id": 105500, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the clinical features and long-term prognosis of mitochondrial fatty acid \u03b2-oxidation defects (FAODs) in children, including the role of alanine aminotransferase (ALAT) as a biomarker.", "results_summary": "The study found that increased blood alanine aminotransferase (ALAT) levels were a frequent symptom (82%) in children with FAODs, often associated with hepatic symptoms like hepatomegaly and steatosis. However, the study did not focus on alanine as a supplement but rather as a biomarker of liver involvement in FAODs.", "population_specificity": "Children aged <6 years diagnosed with FAODs in France, confirmed by enzymatic and/or molecular analyses.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:40.736809+00:00"}
{"study_id": 105501, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the relationship between ALT flares during PEG-IFN therapy and HBV genotypes (wild-type vs. mutants) and to study the kinetics of HBeAg and HBsAg levels during these flares.", "results_summary": "Host-induced ALT flares were associated with wild-type HBV and led to significant declines in HBV DNA, HBeAg, and HBsAg, with 64% of wild-type patients achieving HBsAg clearance. Virus-induced flares were linked to PC/BCP mutants and showed stable or increasing HBsAg levels.", "population_specificity": "214 patients treated with PEG-IFN \u00b1 lamivudine for chronic HBV infection.", "effective_dosage": "Not specified", "study_duration": "52 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:43.852474+00:00"}
{"study_id": 105502, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to compare the effects of low-dose arginine combined with sodium phenylbutyrate versus high-dose arginine alone on liver function tests in patients with argininosuccinic aciduria (ASA).", "results_summary": "High-dose arginine therapy increased AST and ALT levels, particularly in patients with elevated baseline aminotransferases, while low-dose arginine combined with sodium phenylbutyrate showed no significant differences in synthetic liver functions.", "population_specificity": "Twelve patients with argininosuccinic aciduria (ASA).", "effective_dosage": "Low-dose arginine (100 mg/kg/day) with sodium phenylbutyrate (500 mg/kg/day) or high-dose arginine alone (500 mg/kg/day).", "study_duration": "One week.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:44.574207+00:00"}
{"study_id": 105503, "supplement_id": 863, "safety_score": "85", "efficacy_score": null, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety of intramuscular extended-release naltrexone (XR-NTX) in opioid-dependent patients with a high prevalence of chronic HCV and HIV infections.", "results_summary": "The study found no statistically significant difference in liver enzyme elevations (AST, ALT, GGT) between XR-NTX and placebo groups, with most elevations occurring in HCV-infected patients. Liver enzyme levels returned to baseline in follow-up, and no specific symptoms were associated with these elevations.", "population_specificity": "Opioid-dependent patients (88% male) with a high prevalence of chronic HCV (88.8%) and HIV (42%) infections.", "effective_dosage": "XR-NTX 380 mg monthly", "study_duration": "Up to 6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:45.128685+00:00"}
{"study_id": 105504, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to determine whether Phyllanthus urinaria was superior to placebo in improving histological NAFLD activity score in patients with NASH.", "results_summary": "Phyllanthus was not superior to placebo in improving NAFLD activity score or individual histological parameters. Small reductions in hepatic steatosis and ballooning within the Phyllanthus group were of limited clinical significance, and no significant differences were observed in liver biochemistry or metabolic profile changes between groups.", "population_specificity": "Patients with histology-proven NASH (n=60, 40 in Phyllanthus group, 20 in placebo group).", "effective_dosage": "Not specified", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:45.307638+00:00"}
{"study_id": 105505, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether a low dose of lipidated curcumin could alter wellness-related measures in healthy middle-aged individuals, including effects on plasma alanine amino transferase activities.", "results_summary": "The study found that curcumin significantly decreased plasma alanine amino transferase activities, indicating potential liver health benefits, among other health-promoting effects.", "population_specificity": "Healthy middle-aged people (40-60 years old)", "effective_dosage": "80 mg/day", "study_duration": "4 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:45.489814+00:00"}
{"study_id": 105506, "supplement_id": 863, "safety_score": "45", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and efficacy of peginterferon alfa-2b (PEG-IFN) as an adjuvant treatment for melanoma patients with nodal involvement post-surgery.", "results_summary": "PEG-IFN significantly improved relapse-free survival (34.8 vs. 25.5 months) but did not affect overall survival. Common adverse reactions included increased ALT/AST, fatigue, and pyrexia, with 33% discontinuing due to side effects.", "population_specificity": "Melanoma patients with microscopic or gross nodal involvement after surgical resection.", "effective_dosage": "6 \u03bcg/kg per week for 8 doses, then 3 \u03bcg/kg per week for up to 252 weeks.", "study_duration": "Up to 252 weeks (approximately 5 years).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:48.500024+00:00"}
{"study_id": 105507, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 45, "quality_score": 75, "study_goal": "The researchers aimed to determine the risk of relapse after discontinuing immunosuppressive therapy in autoimmune hepatitis (AIH) patients in long-term remission and identify factors associated with relapse.", "results_summary": "The study found that 47% of patients relapsed and 42% lost remission after drug withdrawal, with retreatment rates increasing over time (59% at 1 year, 81% at 3 years). Previous combination therapy, concomitant autoimmune disease, and younger age were associated with higher relapse risk.", "population_specificity": "131 AIH patients in long-term remission (from a cohort of 844) across 7 academic and 14 regional centers in the Netherlands.", "effective_dosage": "Not specified", "study_duration": "At least 2 years of remission before tapering", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:49.363731+00:00"}
{"study_id": 105508, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to identify factors associated with favorable treatment responses, including HBeAg loss and seroconversion, in HBeAg-positive chronic hepatitis B patients treated with entecavir.", "results_summary": "The study found that entecavir treatment over 3 years led to high rates of ALT normalization (up to 94.9%) and undetectable HBV-DNA (up to 82.5%), but had a modest effect on HBeAg loss (48.9%). Baseline ALT and HBV-DNA levels were independent predictors of treatment response.", "population_specificity": "Treatment-na\u00efve HBeAg-positive chronic hepatitis B patients (69.4% male, median age 39.4 years, 15.7% with cirrhosis at baseline).", "effective_dosage": "Not specified", "study_duration": "Median treatment period was 25.3 months (range 12-69.6 months).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:50.481072+00:00"}
{"study_id": 105510, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effectiveness of Japanese treatment guidelines for chronic HCV patients with normal alanine aminotransferase (ALT) levels in reducing hepatocellular carcinoma (HCC) incidence.", "results_summary": "The study found that patients with normal ALT and low platelet counts had higher HCC incidence if they did not respond to antiviral therapy, while responders showed no HCC development. Patients with mild fibrosis and low platelets did not develop HCC regardless of treatment response.", "population_specificity": "Patients with chronic HCV infection and normal ALT levels, categorized by platelet counts and ALT ranges.", "effective_dosage": "Not specified (pegylated interferon plus ribavirin used, but exact dosages not detailed).", "study_duration": "Mean observation period of 36.2 \u00b1 16.5 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:53.748203+00:00"}
{"study_id": 105511, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the relationship between serum gamma-glutamyl transferase (GGT) levels and the presence of coronary collateral vessels (CCV) in patients with acute coronary syndrome (ACS), with alanine-aminotransferase (ALT) as one of the measured parameters.", "results_summary": "High levels of GGT and ALT were significantly associated with the absence of CCV in ACS patients, suggesting a potential link between these biomarkers and poor coronary collateral development.", "population_specificity": "178 patients with ACS (75.3% male, mean age 62 \u00b1 10 years) and >80% coronary artery stenosis.", "effective_dosage": "Not specified", "study_duration": "Not specified (cross-sectional study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:53.870012+00:00"}
{"study_id": 105512, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 90, "study_goal": "The researchers aimed to compare the safety and efficacy of telbivudine versus lamivudine in treating decompensated cirrhosis due to chronic HBV infection, focusing on viral suppression, ALT normalization, and clinical outcomes.", "results_summary": "Telbivudine showed higher rates of viral suppression and ALT normalization compared to lamivudine, with a trend toward improved survival and significant improvement in glomerular filtration rate. No cases of lactic acidosis were reported.", "population_specificity": "Treatment-naive patients with decompensated HBV cirrhosis (n=232) across 80 academic hospitals.", "effective_dosage": "Telbivudine 600 mg once daily or lamivudine 100 mg once daily.", "study_duration": "104 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:54.043387+00:00"}
{"study_id": 105513, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify predictive factors, including alanine aminotransferase (ALT) levels and the \u03b3-GT/ALT ratio, for treatment success in chronic hepatitis C virus genotype 1 (HCV-G1) patients undergoing pegylated interferon-\u03b1 and ribavirin therapy.", "results_summary": "The study found that high ALT levels and a low \u03b3-GT/ALT ratio were associated with higher sustained virological response (SVR) rates, particularly when combined with the IL28B rs12979860 CC genotype. These factors significantly enhanced the predictability of treatment success.", "population_specificity": "264 patients with chronic HCV-G1 infections.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:54.214037+00:00"}
{"study_id": 105509, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the safety and effectiveness of biologic therapy (including ustekinumab and antitumour necrosis factor therapy) in patients with psoriasis and concomitant chronic viral hepatitis (HCV or HBV).", "results_summary": "The study found that biologic therapy was generally effective and safe for most patients with HCV and HBV infection, with 18 of 26 treatments achieving PASI 75 improvement. However, there were isolated cases of viral load increases, liver enzyme elevations, and hepatocellular carcinoma in HCV patients.", "population_specificity": "Patients with psoriasis and concurrent HCV (20 patients) or HBV (5 patients) infection.", "effective_dosage": "Not specified for Alanine (study focused on biologic agents: etanercept, adalimumab, ustekinumab, infliximab).", "study_duration": "Not specified (follow-up period mentioned but duration not detailed).", "interactions": "None mentioned (study focused on viral hepatitis interactions with biologics, not Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:54.394068+00:00"}
{"study_id": 105514, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to assess the tolerability and activity of crizotinib in patients with ALK-positive non-small-cell lung cancer (NSCLC), including safety, pharmacokinetics, and tumor response.", "results_summary": "Crizotinib showed a 60.8% objective response rate, with a median progression-free survival of 9.7 months and generally manageable adverse events, mostly grade 1 or 2. The most common severe adverse events included raised alanine aminotransferase (ALT), neutropenia, and lymphopenia.", "population_specificity": "Patients with ALK-positive stage III or IV NSCLC.", "effective_dosage": "250 mg twice daily.", "study_duration": "Administered in 28-day cycles, with some patients continuing beyond progression for perceived clinical benefit.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:57.690074+00:00"}
{"study_id": 105515, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to compare the efficacy of interferon plus ribavirin treatment in HBV/HCV coinfection versus HCV mono-infection, focusing on virological response and ALT normalization.", "results_summary": "The study found that HBV/HCV coinfection patients had significantly lower ALT normalization rates compared to HCV mono-infection patients, while ETVR and SVR were similar between the two groups. HCV relapse rates did not differ significantly between coinfection and mono-infection patients.", "population_specificity": "Patients with HBV/HCV coinfection and HCV mono-infection.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:58.185077+00:00"}
{"study_id": 105516, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare the effects of aerobic training (AT) versus aerobic plus resistance training (AT+RT) on noninvasive biomarkers of NAFLD, including alanine transaminase (ALT), in obese adolescents.", "results_summary": "The AT+RT protocol significantly reduced ALT levels, improved adiponectin concentrations, and lowered inflammatory biomarkers compared to AT alone, suggesting a beneficial effect on NAFLD-related markers. The study also found that changes in glycemia, insulin, and HOMA-IR were predictors of improved adiponectin levels.", "population_specificity": "Postpubertal obese adolescents diagnosed with NAFLD.", "effective_dosage": "Not specified (exercise-based intervention).", "study_duration": "1 year.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:59.049691+00:00"}
{"study_id": 105520, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the prevalence and clinical associations of portal hypertension (PHT) in children with biliary atresia (BA), including evaluating liver function markers such as alanine aminotransferase (ALT).", "results_summary": "The study found that ALT levels were similar across PHT categories, but other markers like AST, albumin, and bilirubin showed significant differences between definite and absent PHT. Alanine aminotransferase did not correlate with PHT severity.", "population_specificity": "Children with biliary atresia receiving medical management at Childhood Liver Disease Research and Education Network sites.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:02.127682+00:00"}
{"study_id": 105517, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety, recommended dose, and efficacy of transarterial chemoembolization using fine cisplatin powder and gelatin particles for treating multifocal hepatocellular carcinoma.", "results_summary": "The study found that the treatment was well tolerated with no dose-limiting toxicities, and tumor response rates were 25.6% by RECIST and 64.1% by EASL criteria at the recommended dose of 65 mg/m\u00b2. Adverse events included increased alanine aminotransferase levels (21.7%) and other grade 3 or higher toxicities.", "population_specificity": "Patients with multifocal hepatocellular carcinoma.", "effective_dosage": "65 mg/m\u00b2 (recommended dose).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:02.571545+00:00"}
{"study_id": 105519, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the clinicopathological features of liver injury, including the role of elevated serum alanine aminotransferase (ALT) levels, in diabetes mellitus (DM) patients, particularly focusing on nonalcoholic fatty liver disease (NAFLD).", "results_summary": "The study found that 28.6% of DM patients had elevated serum ALT levels (\u226531 IU/L), with alcohol consumption having no significant effect on ALT levels. Among NAFLD patients, male DM patients showed higher frequencies of NASH and advanced-stage NASH compared to non-DM males.", "population_specificity": "Japanese patients with diabetes mellitus (DM) and histologically proven nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:02.995336+00:00"}
{"study_id": 105521, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate the efficacy and safety of ipilimumab plus fotemustine in patients with metastatic melanoma, including those with brain metastases, but did not specifically focus on Alanine.", "results_summary": "The study found that 24% of patients experienced grade 3 or 4 increases in alanine aminotransferase or aspartate aminotransferase concentrations, indicating liver toxicity, but this was not the primary focus of the research.", "population_specificity": "Patients 18 years or older with measurable, locally advanced, unresectable stage III or stage IV melanoma, including those with asymptomatic brain metastases.", "effective_dosage": "Not applicable (study did not focus on Alanine supplementation).", "study_duration": "Induction treatment lasted up to week 24, with maintenance treatment continuing beyond.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:03.708422+00:00"}
{"study_id": 105518, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "To investigate the hepatoprotective effect of MK615 (a Japanese apricot extract) on alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in both animal models and human patients with liver disorders.", "results_summary": "MK615 significantly reduced plasma ALT and AST levels in rats with induced hepatic injury and in human patients with liver disorders, including hepatitis C, non-alcoholic fatty liver disease, and autoimmune liver disease. Histopathological improvements were also observed in the animal model.", "population_specificity": "Wistar rats and 58 human patients with liver disorders (hepatitis C, non-alcoholic fatty liver disease, autoimmune liver disease).", "effective_dosage": "13 g/d of Misatol ME (containing MK615) for humans; 4 mL/kg MK615 solution for rats.", "study_duration": "12 weeks for humans; 7 days for rats.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:03.802680+00:00"}
{"study_id": 105522, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to characterize the population pharmacokinetics of sepantronium bromide (YM155) and identify significant covariates affecting its clearance, including alanine aminotransferase (ALT).", "results_summary": "The study found that ALT, along with creatinine clearance and cancer type, significantly influenced sepantronium's clearance, with creatinine clearance being the most impactful. Other patient characteristics like age, gender, and race did not significantly affect clearance.", "population_specificity": "Patients with non-small cell lung cancer, hormone-refractory prostate cancer, or unresectable stage III/IV melanoma.", "effective_dosage": "4.8 mg/m\u00b2/day as a continuous intravenous infusion over 7 days every 21 days.", "study_duration": "7-day infusion cycles repeated every 21 days.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:06.960870+00:00"}
{"study_id": 105523, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy of interferon (IFN)-\u03b1-based therapy, including its impact on alanine aminotransferase levels, in treating Hepatitis delta virus (HDV) infection.", "results_summary": "High-dose IFN-\u03b1 monotherapy was found to be more effective than PEG-IFN-\u03b1 for HDV treatment, with efficacy rates around 30%. Normalization of alanine aminotransferase levels was rare in untreated patients.", "population_specificity": "Adults with Hepatitis delta virus (HDV) infection (pediatric studies were excluded).", "effective_dosage": "High-dose and low-dose IFN-\u03b1, as well as PEG-IFN-\u03b1 (specific dosages not detailed in abstract).", "study_duration": "1 year of treatment, with follow-up 24 weeks after end of treatment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:07.819878+00:00"}
{"study_id": 105524, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the effects of ursodeoxycholic acid (UDCA) on pruritus, liver test results (including alanine aminotransferase (ALT) levels), and fetal outcomes in women with intrahepatic cholestasis of pregnancy (ICP).", "results_summary": "UDCA was associated with significant improvements, including resolution of pruritus, normalization or reduction of serum ALT levels, and reduced serum bile acids, as well as improved fetal outcomes such as fewer premature births and reduced fetal distress.", "population_specificity": "Pregnant women with intrahepatic cholestasis of pregnancy (ICP).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract (though one group received dexamethasone for 1 week followed by placebo for 2 weeks).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:08.493338+00:00"}
{"study_id": 105525, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers were reporting a unique case of autoimmune sclerosing cholangitis in a child, noting biochemical anomalies including elevated alanine aminotransferase, but did not specifically study alanine's effects.", "results_summary": "The study reported elevated alanine aminotransferase levels in a pediatric patient with autoimmune sclerosing cholangitis, which normalized after 21 weeks of treatment with ursodeoxycholic acid and immunosuppressants. The abstract does not focus on alanine's direct effects or mechanisms.", "population_specificity": "10-year-old Danish boy with severe small duct autoimmune sclerosing cholangitis and Crohn colitis.", "effective_dosage": "Not specified", "study_duration": "Treatment effects monitored over 72 weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:10.513730+00:00"}
{"study_id": 105528, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to clarify the interpretation of elevated alanine aminotransferase (ALT) levels and address common misconceptions about its clinical significance in detecting acute liver injury.", "results_summary": "The study highlights that ALT is not a direct measure of liver function, severity of injury, or predictor of future liver damage, but remains a useful biomarker when properly understood and applied. It critiques the widespread misinterpretation of ALT elevations and suggests better approaches for patient evaluation.", "population_specificity": "Not specified (general discussion on ALT interpretation)", "effective_dosage": "Not available", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:11.516343+00:00"}
{"study_id": 105526, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether long-term low-dose PegIFN\u03b1-2a administration could prevent hepatocellular carcinoma (HCC) in chronic hepatitis C patients, with a focus on the role of alanine aminotransferase (ALT) normalization.", "results_summary": "The study found that low-dose PegIFN\u03b1-2a reduced HCC incidence, particularly in patients with undetectable hepatitis C virus RNA, normalized ALT (\u226440 IU/L), or low alpha-fetoprotein (AFP) levels at 24 weeks. The PegIFN\u03b1-2a group showed significantly lower HCC rates compared to the control group.", "population_specificity": "Chronic hepatitis C patients without a history of HCC.", "effective_dosage": "90 \u03bcg PegIFN\u03b1-2a administered weekly or bi-weekly.", "study_duration": "At least 1 year.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:12.607937+00:00"}
{"study_id": 105529, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effects of ursodeoxycholic acid on patients with nonalcoholic steatohepatitis, including its impact on alanine transaminase levels.", "results_summary": "The study found no significant difference in alanine transaminase activity between ursodeoxycholic acid-treated patients and control patients. Lobular inflammation improved in the high-dose subgroup, but fibrosis showed a tendency to increase.", "population_specificity": "Patients with nonalcoholic steatohepatitis", "effective_dosage": "High-dose subgroup (specific amount not stated)", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:13.440115+00:00"}
{"study_id": 105527, "supplement_id": 863, "safety_score": "80", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to compare the efficacy and safety of two sequential treatment regimens (PEG-IFN followed by LdT vs. LdT followed by PEG-IFN) in HBeAg-negative chronic hepatitis B patients with elevated alanine aminotransferase (ALT).", "results_summary": "The LdT-first group showed a significantly higher virological response rate (46.7%) and lower ALT levels compared to the PEG-IFN-first group (13.3%). The sequential treatment was deemed safe, with minimal adverse events.", "population_specificity": "Adult patients with biopsy-proven HBeAg-negative chronic hepatitis B, elevated ALT, and serum HBV DNA \u2265 2,000 IU/ml (86% male, median age 48 years).", "effective_dosage": "PEG-IFN 180 \u03bcg/week for 24 weeks; LdT 600 mg/day for 24 weeks.", "study_duration": "48 weeks (24 weeks per treatment) plus 24-week follow-up.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:13.996000+00:00"}
{"study_id": 105532, "supplement_id": 863, "safety_score": "85", "efficacy_score": null, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the potential for drug-induced liver injury associated with orlistat by analyzing liver function test data from clinical trials.", "results_summary": "The study found no significant difference in liver function abnormalities (ALT and bilirubin levels) between orlistat and placebo, indicating no signal for hepatic damage in clinical studies. The small apparent effect was partly due to longer exposure to orlistat.", "population_specificity": "Over 10,000 subjects from randomized clinical trials of orlistat.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:17.007093+00:00"}
{"study_id": 105530, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the safety, pharmacokinetics, and antimyeloma activity of lucatumumab, a monoclonal antibody, in patients with relapsed/refractory multiple myeloma.", "results_summary": "The study found that lucatumumab was well tolerated up to 4.5 mg/kg, with reversible mild-to-moderate infusion reactions as common adverse events. Some patients experienced stable disease (43%) or a partial response (4%), indicating modest clinical activity.", "population_specificity": "Patients with relapsed/refractory multiple myeloma.", "effective_dosage": "1.0, 3.0, 4.5, or 6.0 mg/kg once weekly for 4 weeks.", "study_duration": "4 weeks (with some patients receiving an additional cycle).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:17.195050+00:00"}
{"study_id": 105531, "supplement_id": 863, "safety_score": "70", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to determine whether extending peginterferon \u03b1-2a (PegIFN) treatment from 48 to 96 weeks improves outcomes in HBeAg-negative patients with chronic hepatitis B, including alanine aminotransferase normalization and HBV DNA suppression.", "results_summary": "Extended PegIFN treatment (96 weeks) improved virological response compared to 48 weeks, with higher rates of alanine aminotransferase normalization and HBV DNA suppression, though HBsAg clearance remained low. Combination with lamivudine did not enhance efficacy, and discontinuation rates due to adverse events were similar across groups.", "population_specificity": "HBeAg-negative patients (mostly genotype D) chronically infected with hepatitis B virus.", "effective_dosage": "180 \u03bcg PegIFN weekly for 48 weeks, followed by 135 \u03bcg weekly for an additional 48 weeks in extended treatment groups.", "study_duration": "48 or 96 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:18.048410+00:00"}
{"study_id": 105534, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to determine whether therapeutic doses of acetaminophen (up to 4 g/day) affect serum alanine aminotransferase (ALT) levels in subjects who consumed ethanol.", "results_summary": "The study found no significant difference in mean ALT level changes between acetaminophen and placebo groups on day 4 (0.0 U/L difference). No cases of liver dysfunction, failure, or death were reported.", "population_specificity": "Subjects who consumed ethanol and received acetaminophen or placebo.", "effective_dosage": "Up to 4 g/day of acetaminophen.", "study_duration": "4 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:19.448207+00:00"}
{"study_id": 105533, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to investigate whether preprocedural high-dose atorvastatin decreases the incidence of contrast-induced nephropathy (CIN) and protects renal function after emergency PCI, not specifically focusing on Alanine.", "results_summary": "The study found that preprocedural high-dose atorvastatin significantly reduced the incidence of CIN (2.6% vs. 15.7%) and improved renal function markers post-PCI, but did not focus on Alanine's effects.", "population_specificity": "Statin-naive patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing emergency PCI (n = 161).", "effective_dosage": "Atorvastatin 80 mg preprocedurally, followed by 40 mg/day long-term.", "study_duration": "Follow-up included 48 and 72 hours post-PCI, with long-term atorvastatin administration.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:20.652546+00:00"}
{"study_id": 105535, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare ZIC2 molecular findings in Brazilian patients with holoprosencephaly (HPE) to identify genotype-phenotype correlations, including the role of alanine tract expansions.", "results_summary": "The study identified five ZIC2 gene variants, including an alanine tract expansion (p.Ala469_470dup), with only two mutations in classic HPE likely medically significant. Variants in the microform group were not pathogenic, and histidine tract expansion was polymorphic across ethnic groups.", "population_specificity": "105 Brazilian patients within the clinical spectrum of HPE (classic and microform groups).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:21.799417+00:00"}
{"study_id": 105536, "supplement_id": 863, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety of coadministration of statin with fenofibrate, particularly focusing on adverse events related to liver enzymes like alanine aminotransferase (ALT).", "results_summary": "The study found that statin-fenofibrate combination therapy was generally well-tolerated, with no significant differences in adverse events compared to statin monotherapy, except for a higher incidence of elevated ALT levels (\u22653 times upper limit of normal) in the combination group. No cases of myopathy or rhabdomyolysis were reported.", "population_specificity": "1,628 subjects from 6 randomized controlled trials, likely patients with mixed dyslipidemia or high risk for coronary heart disease.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "Statin-fenofibrate combination therapy was studied, but no other specific interactions mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:23.463147+00:00"}
{"study_id": 105537, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety and efficacy of pitavastatin and atorvastatin in reducing elevated hepatic enzyme levels, specifically alanine transaminase (ALT), in patients with mild-to-moderate hepatic enzyme elevation.", "results_summary": "Both pitavastatin and atorvastatin significantly reduced ALT levels and hepatic steatosis in patients with persistently elevated ALT, with comparable efficacy and minimal severe adverse effects.", "population_specificity": "Patients with mild-to-moderate elevated ALT (50-100 IU/L) and elevated LDL cholesterol (\u22653.36 mmol/L), nonalcoholic and serologically negative for viral hepatitis markers.", "effective_dosage": "Pitavastatin 2-4 mg/day, atorvastatin 10-20 mg/day.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:23.676201+00:00"}
{"study_id": 105538, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to determine whether the intermittent Pringle manoeuvre (IPM) reduces blood loss during liver resection and its impact on postoperative liver function, including alanine aminotransferase levels.", "results_summary": "The study found no reduction in blood loss with IPM compared to no Pringle manoeuvre (NPM). Postoperative serum alanine aminotransferase levels were higher in the IPM group, and there were more complications.", "population_specificity": "Patients undergoing elective open hepatectomy, stratified by presence or absence of cirrhosis.", "effective_dosage": "Not applicable", "study_duration": "Duration of the surgical intervention (not specified beyond the study period May 2008 to April 2011).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:25.627013+00:00"}
{"study_id": 105539, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 70, "study_goal": "The researchers aimed to assess the effects of Pelargonium sidoides extract on children with transient hypogammaglobulinemia of infancy (THI) experiencing upper respiratory tract infections (URTI).", "results_summary": "The Pelargonium sidoides group showed increased appetite and some benefits for nasal congestion and cough recovery, though these effects were not statistically significant. The study concluded that larger trials are needed to confirm these findings.", "population_specificity": "Children diagnosed with transient hypogammaglobulinemia of infancy (THI) experiencing upper respiratory tract infections (URTI).", "effective_dosage": "Not specified", "study_duration": "1 week", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:25.702249+00:00"}
{"study_id": 105540, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the safety profile and efficacy of combined erlotinib and pemetrexed treatment in pretreated non-small cell lung cancer (NSCLC) patients, not specifically Alanine.", "results_summary": "The study found that the combination therapy was well-tolerated, with dose-limiting toxicities including grade 3 serum alanine aminotransferase elevation, grade 4 neutropenia, and grade 3 diarrhea. Partial response was achieved in three patients, and stable disease was maintained in five patients.", "population_specificity": "Patients with stage III/IV nonsquamous NSCLC who had progressed after first-line chemotherapy.", "effective_dosage": "Pemetrexed 500 mg/m\u00b2 intravenously every 21 days; erlotinib 100 mg or 150 mg orally on days 2-16.", "study_duration": "Not explicitly stated, but treatment cycles were every 21 days.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:28.076214+00:00"}
{"study_id": 105541, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety of isoniazid (INH) prophylaxis for latent tuberculosis infection (LTBI) in ustekinumab-treated psoriasis patients, including monitoring alanine transaminase levels as a marker of liver toxicity.", "results_summary": "The study found that markedly abnormal alanine transaminase values occurred with comparable incidences between control and ustekinumab-treated patients, and INH prophylaxis was generally well tolerated with low discontinuation rates due to toxicity. No cases of LTBI reactivation were observed in patients receiving concomitant INH.", "population_specificity": "Psoriasis patients (3177 participants across five phase III trials in North America, Europe, and Asia).", "effective_dosage": "Ustekinumab (45 or 90 mg); INH dosage not specified.", "study_duration": "Follow-up through week 28.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:28.676049+00:00"}
{"study_id": 105543, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to characterize case definitions for recent hepatitis C virus (HCV) infection and explore heterogeneity in studies, including the role of alanine aminotransferase (ALT) elevation as a diagnostic criterion.", "results_summary": "The study found that ALT elevation was a frequently used criterion (68%) for defining recent HCV infection, but thresholds varied widely (2-20 times the upper limit of normal). It highlighted significant heterogeneity in case definitions across studies.", "population_specificity": "Studies of recent HCV infection cited between January 2000 and June 2011.", "effective_dosage": "Not available", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:28.708775+00:00"}
{"study_id": 108876, "supplement_id": 881, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the dual role of antioxidants in chemotherapy, examining their potential to either mitigate toxicity or interfere with treatment efficacy.", "results_summary": "The study found that antioxidants can both neutralize harmful oxidants, maintaining redox balance, and potentially interfere with chemotherapy by scavenging reactive oxygen species. The outcomes of antioxidant supplementation during chemotherapy depend on the tumor cellular context.", "population_specificity": "Not specified (general discussion of antioxidants in chemotherapy contexts).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "Chemotherapy agents (potential interference or alleviation of toxicity).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:36.462095+00:00"}
